Publications

Creutzberg CL, Kim JW, Eminowicz G, Allanson E, Eberst L, Kim SI, Nout RA, Park JY, Lorusso D, Mileshkin L, Ottevanger PB, Brand A, Mezzanzanica D, Oza A, Gebski V, Pothuri B, Batley T, Gordon C, Mitra T, White H, Howitt B, Matias-Guiu X, Ray-Coquard I, Gaffney D, Small W Jr, Miller A, Concin N, Powell MA, Stuart G, Bookman MA; participants of the 2023 Gynecologic Cancer InterGroup Endometrial Cancer Consensus Conference on Clinical Research. "Clinical research in endometrial cancer: consensus recommendations from the Gynecologic Cancer InterGroup." Lancet Oncol. 2024 Sep;25(9):e420-e431. doi: 10.1016/S1470-2045(24)00192-X. PMID: 39214113.

Sehouli J, Boer J, Brand AH, Oza AM, O'Donnell J, Bennett K, Glaspool R, Lee CK, Ethier JL, Harter P, Seebacher-Shariat V, Chang TC, Cohen PA, van Gorp T, Chavez-Blanco A, Welch S, Hranovska H, O'Toole S, Lok CAR, Madariaga A, Rauh-Hain JA, Perez Fidalgo A, Tan D, Michels J, Pothuri B, Fujiwara N, Rosengarten O, Nishio H, Kim SI, Mukopadhyay A, Piovano E, Cecere SC, Kohn EC, Mukherjee U, Nasser S, Lindemann K, Croke J, Chen X, Geissler F, Bookman MA. "How to optimize and evaluate diversity in gynecologic cancer clinical trials: statements from the GCIG Barcelona Meeting." Int J Gynecol Cancer. 2024 Nov 4;34(11):1677-1684. doi: 10.1136/ijgc-2024-005982. PMID: 39496422.

Kwon JS, McTaggart-Cowan H, Ferguson SE, Samouëlian V, Lambaudie E, Guyon F, Tidy J, Williamson K, Gleeson N, de Kroon C, van Driel W, Mahner S, Hanker L, Goffin F, Berger R, Eyjólfsdóttir B, Kim JW, Brotto LA, Pataky R, Yeung SST, Chan KKW, Cheung MC, Ubi J, Tu D, Shepherd LE, Plante M. "Cost-effectiveness analysis of simple hysterectomy compared to radical hysterectomy for early cervical cancer: analysis from the GCIG/CCTG CX.5/SHAPE trial." J Gynecol Oncol. 2024 Nov;35(6):e117. doi: 10.3802/jgo.2024.35.e117. Epub 2024 Oct 18. PMID: 39453395; PMCID: PMC11543249.

Plante M, Kwon JS, Ferguson S, Samouëlian V, Ferron G, Maulard A, de Kroon C, Van Driel W, Tidy J, Williamson K, Mahner S, Kommoss S, Goffin F, Tamussino K, Eyjólfsdóttir B, Kim JW, Gleeson N, Brotto L, Tu D, Shepherd LE; CX.5 SHAPE investigators; CX.5 SHAPE Investigators. "Simple versus Radical Hysterectomy in Women with Low-Risk Cervical Cancer." N Engl J Med. 2024 Feb 29;390(9):819-829. doi: 10.1056/NEJMoa2308900. PMID: 38416430.

Nohová I, Andrews J, Votan B, Miller A, Sehouli J, Berger R. "Patient involvement in research within the Gynecological Cancer InterGroup: A call to action for a systematic approach: Results from a survey.", Health Sci Rep. 2023 Dec 1;6(12):e1735. doi: 10.1002/hsr2.1735. PMID: 38045625; PMCID: PMC10691166.

Phan NTH, Tran QT, Nguyen NPT, Nguyen HT, Tran LDN, Pham VC, Bennett K, Chavez-Blanco A, Plante M, Suh DH, Nout R, Tan DSP. "Closing the gap for cervical cancer research in Vietnam: current perspectives and future opportunities: a report from the 5th Gynecologic Cancer InterGroup (GCIG) Cervical Cancer Research Network (CCRN) Education Symposium." J Gynecol Oncol. 2023 Sep;34(5):e88. doi: 10.3802/jgo.2023.34.e88. Erratum in: J Gynecol Oncol. 2023 Nov;34(6):e89. doi: 10.3802/jgo.2023.34.e89. PMID: 37668081; PMCID: PMC10482579.

X. Xu, Rao, H., Fan, X., Pang, X., Wang, Y., Zhao, L., Xing, J., Lv, X., Wang, T., Tao, J., Zhang, X., Qian, J., and Lou, H., “HPV‐related cervical diseases: Alteration of vaginal microbiotas and promising potential for diagnosis”, Journal of Medical Virology, vol. 95, no. 1, 2023.

N. Colombo, Gadducci, A., Sehouli, J., Rulli, E., Mäenpää, J., Sessa, C., Montes, A., Ottevanger, N. B., Berger, R., Vergote, I., D'Incalci, M., C Galaz, C., Chekerov, R., Nyvang, G. B., Riniker, S., Herbertson, R., Fossati, R., Barretina-Ginesta, M. P., Deryal, M., Mirza, M. R., Biagioli, E., Iglesias, M., Funari, G., Romeo, M., Tasca, G., Pardo, B., Tognon, G., Rubio-Pérez, M. J., DeCensi, A., De Giorgi, U., Zola, P., P Panici, B., Aglietta, M., Arcangeli, V., Zamagni, C., Bologna, A., Westermann, A., Heinzelmann-Schwarz, V., Tsibulak, I., Wimberger, P., and Poveda, A., “INOVATYON/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/ PLD followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line”, Br J Cancer, vol. 128, no. 8, pp. 1503-1513, 2023.

S. Nagao, Fujiwara, K., Yamamoto, K., Tanabe, H., Okamoto, A., Takehara, K., Saito, M., Fujiwara, H., Tan, D. S. P., Yamaguchi, S., Adachi, S., Kikuchi, A., Hirasawa, T., Yokoi, T., Nagai, T., Sato, T., Kamiura, S., Fujishita, A., Loong, W. Wai, Chan, K., Syks, P., Olawaye, A., Ryu, S. - Y., Shigeta, H., Kondo, E., Yokoyama, Y., Matsumoto, T., Hasegawa, K., and Enomoto, T., “Intraperitoneal Carboplatin for Ovarian Cancer — A Phase 2/3 Trial”, NEJM Evidence, vol. 2, no. 5, 2023.

J. Pfisterer, Joly, F., Kristensen, G., Rau, J., Mahner, S., Pautier, P., El-Balat, A., Kurtz, J. - E., Canzler, U., Sehouli, J., Heubner, M. L., Hartkopf, A. D., Baumann, K., Hasenburg, A., Hanker, L. C., Belau, A., Schmalfeldt, B., Denschlag, D., Park-Simon, T. - W., Selle, F., Jackisch, C., Burges, A., Lück, H. - J., Emons, G., Meier, W., Gropp-Meier, M., Schröder, W., de Gregorio, N., Hilpert, F., and Harter, P., “Optimal Treatment Duration of Bevacizumab as Front-Line Therapy for Advanced Ovarian Cancer: AGO-OVAR 17 BOOST/GINECO OV118/ENGOT Ov-15 Open-Label Randomized Phase III Trial.”, J Clin Oncol, vol. 41, no. 4, pp. 893-902, 2023.

I. Vergote, González-Martín, A., Lorusso, D., Gourley, C., Mirza, M. Raza, Kurtz, J. - E., Okamoto, A., Moore, K., Kridelka, F., McNeish, I., Reuss, A., Votan, B., Bois, Adu, Mahner, S., Ray-Coquard, I., Kohn, E. C., Berek, J. S., Tan, D. S. P., Colombo, N., Zang, R., Concin, N., O'Donnell, D., Rauh-Hain, A., C Herrington, S., Marth, C., Poveda, A., Fujiwara, K., Stuart, G. C. E., Oza, A. M., Bookman, M. A., Mahner, S., Reuss, A., Bois, Adu, Grimm, C., Marth, C., Berger, R., Concin, N., Chang, T. - C., Ochiai, K., Gebski, V., Davis, A., Beale, P., Vergote, I., Kridelka, F., Denys, H., Vandecaveye, V., Reis, F. Jose Canci, Diz, M. Del Pilar, Stuart, G., MacKay, H., Carey, M., Cibula, D., path), P. Dundr (, Dorigo, O., Berek, J., O'Donnell, D., Saadeh, A., Boere, I., Lok, C., Coronado, P., Ottevanger, N., Tan, D. S. P., Ng, J., Martín, A. González, Oaknin, A., Poveda, A., Fidalgo, A. Perez, Rauh-Hain, A., Lu, K., López-Zavala, C., Gómez-García, E. María, Ray-Coquard, I., Paoletti, X., Kurtz, J. - E., Joly, F., Votan, B., Bookman, M., Moore, K., Arend, R., Fujiwara, K., Fujiwara, H., Hasegawa, K., Bruchim, I., Tsoref, D., Oda, K., Okamoto, A., Enomoto, T., Michel, D., Kim, H. - S., Lee, J. - Y., Mukhopadhyay, A., Katsaros, D., Colombo, N., Pignata, S., Lorusso, D., Scambia, G., Kohn, E., Lee, J. - M., McNeish, I., Nicum, S., Farrelly, L., Sehouli, J., Keller, M., Braicu, E., Bjørge, L., Mirza, M. Raza, Auranen, A., Welch, S., Oza, A. M., Heinzelmann, V., Gourley, C., Roxburgh, P., C Herrington, S., Glasspool, R., Zang, R., and Zhu, J., “Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup”, The Lancet Oncology, vol. 23, no. 8, pp. e374 - e384, 2022.

P. Zola, Ciccone, G., Piovano, E., Fuso, L., Di Cuonzo, D., Castiglione, A., Pagano, E., Peirano, E., Landoni, F., Sartori, E., Narducci, F., Bertetto, O., and Ferrero, A., “Effectiveness of Intensive Versus Minimalist Follow-Up Regimen on Survival in Patients With Endometrial Cancer (TOTEM Study): A Randomized, Pragmatic, Parallel Group, Multicenter Trial.”, J Clin Oncol, vol. 40, no. 33, pp. 3817-3827, 2022.

D. M. Gershenson, Miller, A., Brady, W. E., Paul, J., Carty, K., Rodgers, W., Millan, D., Coleman, R. L., Moore, K. N., Banerjee, S., Connolly, K., Secord, A. Alvarez, O'Malley, D. M., Dorigo, O., Gaillard, S., Gabra, H., Slomovitz, B., Hanjani, P., Farley, J., Churchman, M., Ewing, A., Hollis, R. L., C Herrington, S., Huang, H. Q., Wenzel, L., and Gourley, C., “Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial.”, Lancet, vol. 399, no. 10324, pp. 541-553, 2022.

M. McCormack, Gaffney, D., Tan, D., Bennet, K., Chávez-Blanco, A., and Plante, M., “The Cervical Cancer Research Network (Gynecologic Cancer InterGroup) roadmap to expand research in low- and middle-income countries.”, Int J Gynecol Cancer, 2021.

L. M. Burt, McCormak, M., Lecuru, F., Kanyike, D. M., Bvochora-Nsingo, M., Ndlovu, N., Scott, A. A., Anorlu, R. I., Sharma, V., Plante, M., Nyongesa, C., Tigeneh, W., Fakie, N., Suneja, G., and Gaffney, D. K., “Cervix Cancer in Sub-Saharan Africa: An Assessment of Cervical Cancer Management.”, JCO Glob Oncol, vol. 7, pp. 173-182, 2021.

K. M. Schmeler, Pareja, R., Blanco, A. Lopez, Fregnani, J. Humberto, Lopes, A., Perrotta, M., Tsunoda, A. T., Cantú-de-León, D. F., Ramondetta, L. M., Manchana, T., Crotzer, D. R., McNally, O. M., Riege, M., Scambia, G., Carvajal, J. Manuel, Di Guilmi, J., Rendon, G. J., Ramalingam, P., Fellman, B. M., Coleman, R. L., Frumovitz, M., and Ramirez, P. T., “ConCerv: a prospective trial of conservative surgery for low-risk early-stage cervical cancer.”, Int J Gynecol Cancer, vol. 31, no. 10, pp. 1317-1325, 2021.

C. Callens, Vaur, D., Soubeyran, I., Rouleau, E., Just, P. - A., Guillerm, E., Golmard, L., Goardon, N., Sevenet, N., Cabaret, O., Harter, P., González-Martín, A., Fujiwara, K., Cecere, S. Chiara, Colombo, N., Marth, C., Vergote, I., Maenpaa, J., Pujade-Lauraine, E., and Ray-Coquard, I., “Concordance Between Tumor and Germline BRCA Status in High-Grade Ovarian Carcinoma Patients in the Phase III PAOLA-1/ENGOT-ov25 Trial.”, J Natl Cancer Inst, vol. 113, no. 7, pp. 917-923, 2021.

C. Falandry, Rousseau, F., Mouret-Reynier, M. - A., Tinquaut, F., Lorusso, D., Herrstedt, J., Savoye, A. - M., Stefani, L., Bourbouloux, E., Sverdlin, R., D’Hondt, V., Lortholary, A., Brachet, P. - E., Zannetti, A., Malaurie, E., Venat-Bouvet, L., Trédan, O., Mourey, L., Pujade-Lauraine, E., and Freyer, G., “Efficacy and Safety of First-line Single-Agent Carboplatin vs Carboplatin Plus Paclitaxel for Vulnerable Older Adult Women With Ovarian Cancer”, JAMA Oncology, vol. 7, no. 6, p. 853, 2021.

J. - E. Kurtz, Gebski, V., Sukhin, V., Carey, M., Kong, I., Glasspool, R. M., Berek, J. S., Batista, Mde Paiva, Hall, M., Kim, J. - W., Yeoshoua, E., Fujiwara, N., Nam, B. - H., Polleis, S., Lee, J. - Y., Strojna, A., Farrelly, L., Schwameis, R., Fossati, R., Darlington, A. - S., Lai, C. - H., Wright, A. A., Rosenblat, O., Harter, P., Roxburgh, P., Chowdhury, R. Roy, Chang, T. - C., Paoletti, X., and Friedlander, M., “Incorporating patient centered benefits as endpoints in randomized trials of maintenance therapies in advanced ovarian cancer: A position paper from the GCIG symptom benefit committee.”, Gynecol Oncol, 2021.

K. Fujiwara, Fujiwara, H., Yoshida, H., Satoh, T., Yonemori, K., Nagao, S., Matsumoto, T., Kobayashi, H., Bourgeois, H., Harter, P., Mosconi, A. Maria, Vazquez, I. Palacio, Reinthaller, A., Fujita, T., Rowe, P., Pujade-Lauraine, E., and Ray-Coquard, I., "Olaparib plus bevacizumab as maintenance therapy in patients with newly diagnosed, advanced ovarian cancer: Japan subset from the PAOLA-1/ENGOT-ov25 trial", Journal of Gynecologic Oncology, vol. 32, no. 5, 2021.

A. Poveda, Floquet, A., Ledermann, J. A., Asher, R., Penson, R. T., Oza, A. M., Korach, J., Huzarski, T., Pignata, S., Friedlander, M., Baldoni, A., Park-Simon, T. - W., Tamura, K., Sonke, G. S., Lisyanskaya, A., Kim, J. - H., Filho, E. Abdo, Milenkova, T., Lowe, E. S., Rowe, P., Vergote, I., Pujade-Lauraine, E., Korach, J., Huzarski, T., Byrski, T., Pautier, P., Friedlander, M., Harter, P., Colombo, N., Pignata, S., Scambia, G., Nicoletto, M., Nussey, F., Clamp, A., Penson, R., Oza, A., Velasco, A. Poveda, Rodrigues, M., Lotz, J. - P., Selle, F., Ray-Coquard, I., Provencher, D., Aparicio, A. Prat, Boixader, L. Vidal, Scott, C., Tamura, K., Yunokawa, M., Lisyanskaya, A., Medioni, J., Pécuchet, N., Dubot, C., Rouge, Tde la Mott, Kaminsky, M. - C., Weber, B., Lortholary, A., Parkinson, C., Ledermann, J., Williams, S., Banerjee, S., Cosin, J., Hoffman, J., Penson, R., Plante, M., Covens, A., Sonke, G., Joly, F., Floquet, A., Banerjee, S., Hirte, H., Amit, A., Park-Simon, T. - W., Matsumoto, K., Tjulandin, S., Kim, J. Hoon, Gladieff, L., Sabbatini, R., O'Malley, D., Timmins, P., Kredentser, D., Milagro, N. Laínez, Ginesta, M. Pilar Barr, Martorell, A. Tibau, Lista, A. Gómez De, González, B. Ojeda, Mileshkin, L., Mandai, M., Boere, I., Ottevanger, P., Nam, J. - H., Filho, E., Hamizi, S., Cognetti, F., Warshal, D., Dickson-Michelson, E., Kamelle, S., McKenzie, N., Rodriguez, G., Armstrong, D., Chalas, E., Celano, P., Behbakht, K., Davidson, S., Welch, S., Helpman, L., Fishman, A., Bruchim, I., Sikorska, M., Słowińska, A., Rogowski, W., Bidziński, M., Śpiewankiewicz, B., Herraez, A. Casado, Fernández, C. Mendiola, Gropp-Meier, M., Saito, T., Takehara, K., Enomoto, T., Watari, H., Choi, C. Hun, Kim, B. - G., Kim, J. Weon, Hegg, R., and Vergote, I., “Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial”, The Lancet Oncology, vol. 22, no. 5, pp. 620 - 631, 2021.

S. N. Banerjee, Tang, M., O'Connell, R. L., Sjoquist, K., Clamp, A. R., Millan, D., Nottley, S., Lord, R., Mullassery, V. Menon, Hall, M., Gourley, C., Bonaventura, T., Goh, J. C., Sykes, P., Grant, P. T., McNally, O., Alexander, L., Kelly, C., Carty, K., Divers, L., Bradshaw, N., Edmondson, R. J., and Friedlander, M., “A phase 2 study of anastrozole in patients with oestrogen receptor and/progesterone receptor positive recurrent/metastatic granulosa cell tumours/sex-cord stromal tumours of the ovary: The PARAGON/ANZGOG 0903 trial.”, Gynecol Oncol, vol. 163, no. 1, pp. 72-78, 2021.

A. Tjokrowidjaja, Friedlander, M., Lord, S. J., Asher, R., Rodrigues, M., Ledermann, J. A., Matulonis, U. A., Oza, A. M., Bruchim, I., Huzarski, T., Gourley, C., Harter, P., Vergote, I., Scott, C. L., Meier, W., Shapira-Frommer, R., Milenkova, T., Pujade-Lauraine, E., Gebski, V., and Lee, C. K., “Prognostic nomogram for progression-free survival in patients with BRCA mutations and platinum-sensitive recurrent ovarian cancer on maintenance olaparib therapy following response to chemotherapy”, European Journal of Cancer, vol. 154, pp. 190 - 200, 2021.

P. Harter, Sehouli, J., Vergote, I., Ferron, G., Reuss, A., Meier, W., Greggi, S., Mosgaard, B. J., Selle, F., Guyon, F., Pomel, C., Lecuru, F., Zang, R., Avall-Lundqvist, E., Kim, J. - W., Ponce, J., Raspagliesi, F., Kristensen, G., Classe, J. - M., Hillemanns, P., Jensen, P., Hasenburg, A., Ghaem-Maghami, S., Mirza, M. R., Lund, B., Reinthaller, A., Santaballa, A., Olaitan, A., Hilpert, F., and Bois, Adu, “Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer”, New England Journal of Medicine, vol. 385, no. 23, pp. 2123 - 2131, 2021.

P.  Harter, Pautier, P., Van Nieuwenhuysen, E., Reuss, A., Redondo, A., Lindemann, K., Kurzeder, C., Petru, E., Heitz, F., Sehouli, J., Degregorio, N., Wimberger, P., Burges, A., Cron, N., Ledermann, J., Lorusso, D., Paoletti, X., and Marme, F., Atezolizumab in combination with bevacizumab and chemotherapy versus bevacizumab and chemotherapy in recurrent ovarian cancer - a randomized phase III trial (AGO-OVAR 2.29/ENGOT-ov34). Int J Gynecol Cancer, vol. 30, no. 12, pp. 1997-2001, 2020.PubMed

J.  Pfisterer, Shannon, C. M., Baumann, K., Rau, J., Harter, P., Joly, F., Sehouli, J., Canzler, U., Schmalfeldt, B., Dean, A. P., Hein, A., Zeimet, A. G., Hanker, L. C., Petit, T., Marme, F., El-Balat, A., Glasspool, R., de Gregorio, N., Mahner, S., Meniawy, T. M., Park-Simon, T. - W., Mouret-Reynier, M. - A., Costan, C., Meier, W., Reinthaller, A., Goh, J. C., L'Haridon, T., Hay, S. Baron, Kommoss, S., Bois, Adu, and Kurtz, J. - E., Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial, Lancet Oncol, vol. 21, no. 5, pp. 699-709, 2020.PubMed

A.  Tjokrowidjaja, Lee, C. K., Friedlander, M., Gebski, V., Gladieff, L., Ledermann, J., Penson, R., Oza, A., Korach, J., Huzarski, T., Manso, L., Pisano, C., Asher, R., Lord, S. J., Kim, S. Ik, Lee, J. - Y., Colombo, N., Park-Simon, T. - W., Fujiwara, K., Sonke, G., Vergote, I., Kim, J. - W., and Pujade-Lauraine, E., Concordance between CA-125 and RECIST progression in patients with germline BRCA-mutated platinum-sensitive relapsed ovarian cancer treated in the SOLO2 trial with olaparib as maintenance therapy after response to chemotherapy, European Journal of Cancer, vol. 139, pp. 59 - 67, 2020.DOI

I.  Ray-Coquard, Harter, P., Lorusso, D., Dalban, C., Vergote, I., Fujiwara, K., Gladieff, L., Lack, H. - J., Floquet, A., Chevalier-Place, A., Schnelzer, A., Pignata, S., Selle, F., Sehouli, J., Brocard, F., Mangili, G., Pautier, P., De Giorgi, U., Provansal, M., and Heudel, P. - E., Effect of Weekly Paclitaxel With or Without Bevacizumab on Progression-Free Rate Among Patients With Relapsed Ovarian Sex Cord-Stromal Tumors, JAMA Oncology, vol. 6, no. 12, p. 1923, 2020.DOI

W.  Small, Peltecu, G., Puiu, A., Corha, A., Cocráă, E., Cigăran, R. Gabriela, Plante, M., Jhingran, A., Stang, K., Gaffney, D., Bacon, M., and McCormack, M., Cervical cancer in Eastern Europe: review and proceedings from the Cervical Cancer Research Conference., Int J Gynecol Cancer, 2020.PubMed

I.  Rohr, Alavi, S., Richter, R., Keller, M., Chekerov, R., Oskay-Özcelik, G., Heinrich, M., Taskiran, C., Joly, F., Berger, R., Bois, Adu, Gornjec, A., Vergote, I., Achimas-Cadariu, P., Lorusso, D., Maenpaa, J., and Sehouli, J., Expectations and preferences of patients with primary and relapsed ovarian cancer to maintenance therapy: A NOGGO/ENGOT-ov22 and GCIG survey (Expression IV)., Int J Gynecol Cancer, vol. 30, no. 4, pp. 509-514, 2020.PubMed

F.  Falcone, Maggiore, U. Leone Robe, Di Donato, V., Perrone, A. Myriam, Frigerio, L., Bifulco, G., Polterauer, S., Casadio, P., Cormio, G., Masciullo, V., Malzoni, M., and Greggi, S., Fertility-sparing treatment for intramucous, moderately differentiated, endometrioid endometrial cancer: a Gynecologic Cancer Inter-Group (GCIG) study, Journal of Gynecologic Oncology, vol. 31, 2020.DOI

X.  Paoletti, Lewsley, L. - A., Daniele, G., Cook, A., Yanaihara, N., Tinker, A., Kristensen, G., Ottevanger, P. B., Aravantinos, G., Miller, A., Boere, I. A., Fruscio, R., Reyners, A. K. L., Pujade-Lauraine, E., Harkin, A., Pignata, S., Kagimura, T., Welch, S., Paul, J., Karamouza, E., and Glasspool, R. M., Assessment of Progression-Free Survival as a Surrogate End Point of Overall Survival in First-Line Treatment of Ovarian Cancer: A Systematic Review and Meta-analysis, JAMA Netw Open, vol. 3, no. 1, p. e1918939, 2020.PubMed

M. Bagnoli, Shi, T. Yan, Gourley, C., Speiser, P., Reuss, A., Nijman, H. W., Creutzberg, C. L., Scholl, S., Negrouk, A., Brady, M. F., Hasegawa, K., Oda, K., McNeish, I. A., Kohn, E. C., Oza, A. M., MacKay, H., Millan, D., Bennett, K., Scott, C., and Mezzanzanica, D., Gynecological Cancers Translational, Research Implementation, and Harmonization: Gynecologic Cancer InterGroup Consensus and Still Open Questions., Cells, vol. 8, no. 3, 2019.PubMed 

G. F. Vercellino, Erdemoglu, E., Lichtenberg, P., Muallem, M. Z., Richter, R., Abu-Rustum, N. R., Plante, M., Lecuru, F., Greggi, S., Monk, B. J., Sagae, S., Denkert, C., Keller, M., Alhakeem, M., Hellriegel, M., Dackelmann, A. M., Chiantera, V., and Sehouli, J., A GCIG international survey: clinical practice patterns of sentinel lymph node biopsies in cervical cancer., Arch Gynecol Obstet, 2019.PubMed 
 

I. Ray-Coquard, Pautier, P., Pignata, S., Perol, D., Gonzalez-Martan, A., Berger, R., Fujiwara, K., Vergote, I., Colombo, N., Maenpaa, J., Selle, F., Sehouli, J., Lorusso, D., Alía, E. M. Guerra, Reinthaller, A., Nagao, S., Lefeuvre-Plesse, C., Canzler, U., Scambia, G., Lortholary, A., Marme, F., Combe, P., de Gregorio, N., Rodrigues, M., Buderath, P., Dubot, C., Burges, A., You, B., Pujade-Lauraine, E., and Harter, P., Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer, New England Journal of Medicine, vol. 381, no. 25, pp. 2416 - 2428, 2019.DOI 

I. Ray-Coquard, Cibula, D., Mirza, M. R., Reuss, A., Ricci, C., Colombo, N., Koch, H., Goffin, F., Gonzleza Martin, A., Ottevanger, P. B., Baumann, K., Bjarge, L., Lesoin, A., Burges, A., Rosenberg, P., Groppa Meier, M., Harrela, M., Harter, P., Frenel, J., Minarik, T., Pisano, C., Hasenburg, A., Merger, M., and Bois, A., Final results from GCIG/ENGOT/AGOOVAR 12, a randomised placebo controlled phase III trial of nintedanib combined with chemotherapy for newly diagnosed advanced ovarian cancer, International Journal of Cancer, vol. 146, no. 2, pp. 439 - 448, 2019.DOI

 
F. R. Lecuru, McCormack, M., Hillemanns, P., Anota, A., Leitao, M., Mathevet, P., Zweemer, R., Fujiwara, K., Zanagnolo, V., Eriksson, A. Gerda Zahl, Hudson, E., Ferron, G., and Plante, M.,SENTICOL III: an international validation study of sentinel node biopsy in early cervical cancer. A GINECO, ENGOT, GCIG and multicenter study, International Journal of Gynecologic Cancer, vol. 29, no. 4, pp. 829 - 834, 2019.DOI 

F. Heitz, Harter, P., vall-Lundqvist, E., Reuss, A., Pautier, P., Cormio, G., Colombo, N., Reinthaller, A., Vergote, I., Poveda, A., Ottevanger, P. B., Hanker, L. C., Leminen, A., Alexandre, J., Canzler, U., Sehouli, J., Herrstedt, J., Fiane, B., Merger, M., and A Bois, du, Early tumor regrowth is a contributor to impaired survival in patients with completely resected advanced ovarian cancer. An exploratory analysis of the Intergroup trial AGO-OVAR 12., Gynecol Oncol, vol. 152, no. 2, pp. 235-242, 2019.PubMed 

I. Vergote, A. Bois, du, Floquet, A., Rau, J., Kim, J. - W., del Campo, J. M., Friedlander, M., Pignata, S., Fujiwara, K., Colombo, N., Mirza, M. R., Monk, B. J., Tsibulak, I., Calvert, P. M., Herzog, T. J., Hanker, L. C., Meunier, J., Lee, J. - Y., Bologna, A., Carrasco-Alfonso, M. J., and Harter, P., Overall survival results of AGO-OVAR16: A phase 3 study of maintenance pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced ovarian cancer, Gynecologic Oncology, vol. 155, no. 2, pp. 186 - 191, 2019.DOI A. Reuss, Bois, Adu, Harter, P., Fotopoulou, C., Sehouli, J., Aletti, G., Guyon, F., Greggi, S., Mosgaard, B. Jul, Reinthaller, A., Hilpert, F., Schade-Brittinger, C., Chi, D. S., and Mahner, S., TRUST: Trial of Radical Upfront Surgical Therapy in advanced ovarian cancer (ENGOT ov33/AGOOVAR OP7)”, International Journal of Gynecologic Cancer, vol. 29, no. 8, pp. 1327 - 1331, 2019.DOI 

P. Harter, Sehouli, J., Lorusso, D., Reuss, A., Vergote, I., Marth, C., Kim, J. - W., Raspagliesi, F., Lampe, B., Aletti, G., Meier, W., Cibula, D., Mustea, A., Mahner, S., Runnebaum, I. B., Schmalfeldt, B., Burges, A., Kimmig, R., Scambia, G., Greggi, S., Hilpert, F., Hasenburg, A., Hillemanns, P., Giorda, G., von Leffern, I., Schade-Brittinger, C., Wagner, U., and Bois, Adu, A Randomized Trial of Lymphadenectomy in Patients with Advanced Ovarian Neoplasms., N Engl J Med, vol. 380, no. 9, pp. 822-832, 2019.PubMed

V. D. Gonzalez, Samusik, N., Chen, T. J., Savig, E. S., Aghaeepour, N., Quigley, D. A., Huang, Y. - W., Giangarrà, V., Borowsky, A. D., Hubbard, N. E., Chen, S. - Y., Han, G., Ashworth, A., Kipps, T. J., Berek, J. S., Nolan, G. P., and Fantl, W. J., “Commonly Occurring Cell Subsets in High-Grade Serous Ovarian Tumors Identified by Single-Cell Mass Cytometry.”, Cell Rep, vol. 22, no. 7, pp. 1875-1888, 2018.PubMed 

M. Leonard Friedlander, Rau, J., Lee, C. Khoon, Meier, W., Lesoin, A., Kim, J. - W., Poveda, A. M., Buck, M., Scambia, G., Shimada, M., Hilpert, F., King, M. Trudy, Debruyne, P., Bologna, A., Malander, S., Monk, B. J., Petru, E., Calvert, P., Herzog, T. J., Barrett, C., and A Bois, du, “Quality of life in patients with advanced epithelial ovarian cancer (EOC) randomized to maintenance pazopanib or placebo after first-line chemotherapy in the AGO-OVAR 16 trial.”, Ann Oncol, vol. 29, no. 3, pp. 737-743, 2018.PubMed 

D. K. Gaffney, Hashibe, M., Kepka, D., Maurer, K. A., and Werner, T. L., “Too many women are dying from cervix cancer: Problems and solutions.”, Gynecol Oncol, 2018.PubMed 

B. J. Ager, Gallardo-Rincon, D., de León, D. Cantú, Chávez-Blanco, A., Chuang, L., Dueñas-González, A., Gomez-Garcia, E., Jerez, R., Jhingran, A., McCormack, M., Mileshkin, L., Pérez-Plasencia, C., Plante, M., Poveda, A., and Gaffney, D. K., “Advancing clinical research globally: Cervical cancer research network from Mexico.”, Gynecol Oncol Rep, vol. 25, pp. 90-93, 2018.PubMed 

P. T. Ramirez, Frumovitz, M., Pareja, R., Lopez, A., Vieira, M., Ribeiro, R., Buda, A., Yan, X., Shuzhong, Y., Chetty, N., Isla, D., Tamura, M., Zhu, T., Robledo, K. P., Gebski, V., Asher, R., Behan, V., Nicklin, J. L., Coleman, R. L., and Obermair, A., “Minimally Invasive versus Abdominal Radical Hysterectomy for Cervical Cancer.”, N Engl J Med, vol. 379, no. 20, pp. 1895-1904, 2018.PubMed

G. C. E. Stuart, Kitchener, H. C., Vermorken, J. B., Quinn, M., Small, W., Pujade-Lauraine, E., Chou, H., Wong, M., and Bacon, M., “The Impact of an International Network (Gynecologic Cancer InterGroup) for Clinical Research on Global Capacity for Gynecologic Cancer Clinical Trials.”, Int J Gynecol Cancer, 2017.DOI

W. Small, Bacon, M., Bajaj, A., Chuang, L. T., Fisher, B. J., Harkenrider, M. M., Jhingran, A., Kitchener, H. C., Mileshkin, L. R., Viswanathan, A., and Gaffney, D. K., “Cervical cancer: A global health cis.”, Cancer, vol. 123, no. 13, pp. 2404-2412, 2017.PubMed DOI

F. Joly, Hilpert, F., Okamoto, A., Stuart, G., Ochiai, K., and Friedlander, M., “Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: Recommendations on incorporating patient-reported outcomes in clinical trials in epithelial ovarian cancer”, European Journal of Cancer, vol. 78, pp. 133 - 138, 2017.DOI

J. McGee, Bookman, M., Harter, P., Marth, C., McNeish, I., Moore, K. N., Poveda, A., Hilpert, F., Hasegawa, K., Bacon, M., Gatsonis, C., Brand, A., Kridelka, F., Berek, J., Ottevanger, N., Levy, T., Silverberg, S., Kim, B. - G., Hirte, H., Okamoto, A., Stuart, G., and Ochiai, K., “Fifth Ovarian Cancer Consensus Conference: individualized therapy and patient factors”, Annals of Oncology, vol. 28, no. 4, pp. 702 - 710, 2017.DOI

A. Karam, Ledermann, J. A., Kim, J. - W., Sehouli, J., Lu, K., Gourley, C., Katsumata, N., Burger, R. A., Nam, B. - H., Bacon, M., Ng, C., Pfisterer, J., Bekkers, R. L. M., A. Herráez, C., Redondo, A., Fujiwara, H., Gleeson, N., Rosengarten, O., Scambia, G., Zhu, J., Okamoto, A., Stuart, G., and Ochiai, K., “Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: first-line interventions”, Annals of Oncology, vol. 28, no. 4, pp. 711 - 717, 2017.DOI

M. K. Wilson, Pujade-Lauraine, E., Aoki, D., Mirza, M. R., Lorusso, D., Oza, A. M., A. Bois, du, Vergote, I., Reuss, A., Bacon, M., Friedlander, M., Gallardo-Rincon, D., Joly, F., Chang, S. - J., Ferrero, A. M., Edmondson, R. J., Wimberger, P., Maenpaa, J., Gaffney, D., Zang, R., Okamoto, A., Stuart, G., and Ochiai, K., “Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: recurrent disease”, Annals of Oncology, vol. 28, no. 4, pp. 727 - 732, 2017.DOI

M. A. Bookman, Okamoto, A., Stuart, G., Yanaihara, N., Aoki, D., Bacon, M., Fujiwara, K., González-Martín, A., Harter, P., Kim, J. W., Ledermann, J., Pujade-Lauraine, E., Quinn, M., and Ochiai, K., “Harmonising clinical trials within the Gynecologic Cancer InterGroup: consensus and unmet needs from the Fifth Ovarian Cancer Consensus Conference”, Annals of Oncology, vol. 28, pp. viii30 - viii35, 2017.DOI 

A. F. Leary, Quinn, M., Fujiwara, K., Coleman, R. L., Kohn, E., Sugiyama, T., Glasspool, R., Ray-Coquard, I., Colombo, N., Bacon, M., Zeimet, A., Westermann, A., Gomez-Garcia, E., Provencher, D., Welch, S., Small, W., Millan, D., Okamoto, A., Stuart, G., and Ochiai, K., “Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup (GCIG): clinical trial design for rare ovarian tumours”, Annals of Oncology, vol. 28, no. 4, pp. 718 - 726, 2017.DOI

S. Lheureux, Karakasis, K., Harter, P., Scott, C., Bacon, M., Bryce, J., Le Fur, N., Pujade-Lauraine, E., and Oza, A. M., “Germline BRCA1/2 testing practices in ovarian cancer: Current state and opportunities for new directions.”, Gynecol Oncol, vol. 140, no. 1, p. 94, 2016.PubMed

L. Brotto, Brundage, M., Hoskins, P., Vergote, I. B., Cervantes, A., Casado, H. A., Poveda, A. M., Eisenhauer, E., and Tu, D., “Randomized study of sequential cisplatin-topotecan/carboplatin-paclitaxel versus carboplatin-paclitaxel: effects on quality of life.”, Support Care Cancer, vol. 24, no. 3, p. 1249, 2016.PubMed

A. du Bois, Ktensen, G. B., Ray-Coquard, I., Reuss, A., Pignata, S., Colombo, N., Denison, U., Vergote, I. B., Del Campo, J. M., Ottevanger, P., Heubner, M., Minarik, T., Sevin, E., de Gregorio, N., Bidziński, M., Pfisterer, J., Malander, S., Hilpert, F., Mirza, M. R., Scambia, G., Meier, W., Nicoletto, M. O., Bjørge, L., Lortholary, A., Sailer, M. Oliver, Merger, M., and Harter, P., “Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial.”, Lancet Oncol, vol. 17, no. 1, p. 89, 2016.PubMed

S. Sagae, Monk, B. J., Pujade-Lauraine, E., Gaffney, D. K., Narayan, K., Ryu, S. Young, McCormack, M., Plante, M., Casado, A., Reuss, A., Chávez-Blanco, A., Kitchener, H. C., Nam, B. - H., Jhingran, A., Temkin, S., Mileshkin, L. R., Berns, E. M. J. J., Scholl, S., Doll, C., Abu-Rustum, N. R., Lecuru, F., and Small, W., “Advances and Concepts in Cervical Cancer Trials: A Road Map for the Future.”, Int J Gynecol Cancer, vol. 26, no. 1, p. 207, 2016.PubMed

J. K. Chan, Brady, M. F., Penson, R. T., Huang, H., Birrer, M. J., Walker, J. L., DiSilvestro, P. A., Rubin, S. C., Martin, L. P., Davidson, S. A., Huh, W. K., O'Malley, D. M., Boente, M. P., Michael, H., and Monk, B. J., “Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer.”, N Engl J Med, vol. 374, no. 8, p. 748, 2016.PubMed

P. Harter, Johnson, T., Berton-Rigaud, D., Park, S. - Y., Friedlander, M. Leonard, Del Campo, J. M., Shimada, M., Forget, F., Mirza, M. R., Colombo, N., Zamagni, C., Chan, J. K., Imhof, M., Herzog, T. J., O'Donnell, D., Heitz, F., King, K., Stinnett, S., Barrett, C., Jobanputra, M., Xu, C. - F., and du Bois, A., “BRCA1/2 mutations associated with progression-free survival in ovarian cancer patients in the AGO-OVAR 16 study.”, Gynecol Oncol, vol. 140, no. 3, pp. 443-9, 2016.PubMed

J. A. Ledermann, Embleton, A. C., Raja, F., Perren, T. J., Jayson, G. C., Rustin, G. J. S., Kaye, S. B., Hirte, H., Eisenhauer, E., Vaughan, M., Friedlander, M. Leonard, Gonzalez-Martin, A., Stark, D., Clark, E., Farrelly, L., Swart, A. Marie, Cook, A. D., Kaplan, R. S., and Parmar, M. K. B., “Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial.”, Lancet, vol. 387, no. 10023, pp. 1066-74, 2016.PubMed

A. M. Angarita, Johnson, C. Alonia Lil, Fader, A. Nickles, and Chtianson, M. S., “Fertility preservation: A key survivorship issue for young women with cancer ”, Frontiers in Oncology , vol. 6, no. 102, 2016.DOI

K. Katherine, Julia, B., Valerie, B., Oza, A. M., and Stephanie, L., “Ovarian Cancer and BRCA1/2 Testing: Opportunities to improve clinical care and disease prevention ”, Frontiers in Oncology , vol. 6, no. 00119 , 2016.DOI

S. Temkin, Tanner, E. J., Dewdney, S., and Minasian, L. M., “Reducing overtreatment in gynecologic oncology: the case for less in endometrial and ovarian cancer”, Frontiers in Oncology , vol. 6, no. 00118 , 2016.DOI

K. Harano, Hirakawa, A., Yunokawa, M., Nakamura, T., Satoh, T., Nishikawa, T., Aoki, D., Ito, K., Ito, K., Nakanishi, T., Susumu, N., Takehara, K., Watanabe, Y., Watari, H., and Saito, T., “Prognostic factors in patients with uterine carcinosarcoma: a multi-institutional retrospective study from the Japanese Gynecologic Oncology Group.”, Int J Clin Oncol, vol. 21, no. 1, pp. 168-76, 2016.PubMed

Y. Ikeda, Furusawa, A., Kitagawa, R., Tokinaga, A., Ito, F., Ukita, M., Nomura, H., Yamagami, W., Tanabe, H., Mikami, M., Takeshima, N., and Yaegashi, N., “Practice patterns of adjuvant therapy for intermediate/high recurrence k cervical cancer patients in Japan.”, J Gynecol Oncol, vol. 27, no. 3, p. e29, 2016.PubMed

D. J. Pulford, Harter, P., Floquet, A., Barrett, C., Suh, D. Hoon, Friedlander, M. Leonard, Arranz, J. Angel, Hasegawa, K., Tada, H., Vuylsteke, P., Mirza, M. R., Donadello, N., Scambia, G., Johnson, T., Cox, C., Chan, J. K., Imhof, M., Herzog, T. J., Calvert, P., Wimberger, P., Berton-Rigaud, D., Lim, M. Cheol, Elser, G., Xu, C. - F., and Bois, Adu, “Communicating BRCA research results to patients enrolled in international clinical trials: lessons learnt from the AGO-OVAR 16 study.”, BMC Med Ethics, vol. 17, no. 1, p. 63, 2016.PubMed

A. Floquet, Vergote, I. B., Colombo, N., Fiane, B., Monk, B. J., Reinthaller, A., Calvert, P., Herzog, T. J., Meier, W., Kim, J. - W., Del Campo, J. M., Friedlander, M. Leonard, Pisano, C., Isonishi, S., Crescenzo, R. J., Barrett, C., Wang, K., Mitrica, I., and du Bois, A., “Progression-free survival by local investigator versus independent central review: comparative analysis of the AGO-OVAR16 Trial.”, Gynecol Oncol, vol. 136, no. 1, p. 42, 2015.PubMed

A. M. Poveda, Selle, F., Hilpert, F., Reuss, A., Savarese, A., Vergote, I. B., Witteveen, P., Bamias, A., Scotto, N., Mitchell, L., and Pujade-Lauraine, E., “Bevacizumab Combined With Weekly Paclitaxel, Pegylated Liposomal Doxorubicin, or Topotecan in Platinum-Resistant Recurrent Ovarian Cancer: Analysis by Chemotherapy Cohort of the Randomized Phase III AURELIA Trial.”, J Clin Oncol, vol. 33, no. 32, p. 3838, 2015.PubMed

A. M. Oza, Cook, A. D., Pfisterer, J., Embleton, A. C., Ledermann, J. A., Pujade-Lauraine, E., Ktensen, G. B., Carey, M. S., Beale, P., Cervantes, A., Park-Simon, T. - W., Rustin, G. J. S., Joly, F., Mirza, M. R., Plante, M., Quinn, M., Poveda, A. M., Jayson, G. C., Stark, D., Swart, A. Marie, Farrelly, L., Kaplan, R. S., Parmar, M. K. B., and Perren, T. J., “Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial.”, Lancet Oncol, vol. 16, no. 8, p. 936, 2015.PubMed

C. Khoon Lee, Lord, S., Grunewald, T., Gebski, V., Hardy-Bessard, A. - C., Sehouli, J., Woie, K., Heywood, M., Schauer, C., Vergote, I. B., Scambia, G., Ferrero, A., Harter, P., Pujade-Lauraine, E., and Friedlander, M. Leonard, “Impact of secondary cytoreductive surgery on survival in patients with platinum sensitive recurrent ovarian cancer: analysis of the CALYPSO trial.”, Gynecol Oncol, vol. 136, no. 1, pp. 18-24, 2015.PubMed

S. Mahner, Meier, W., du Bois, A., Brown, C., Lorusso, D., Dell'Anna, T., Cretin, J., Havsteen, H., Bessette, P., Zeimet, A. G., Vergote, I. B., Vasey, P. A., Pujade-Lauraine, E., Gladieff, L., and Ferrero, A., “Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in very platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial.”, Eur J Cancer, vol. 51, no. 3, pp. 352-8, 2015.PubMed

F. T. Roncolato, O'Connell, R., Joly, F., Lanceley, A., Hilpert, F., Okamoto, A., Aotani, E., Pignata, S., Donnellan, P. P., Oza, A. M., Åvall-Lundqvist, E., Berek, J. S., Sjoquist, K. Marie, Gillies, K., Butow, P., Stockler, M. R., King, M. Trudy, and Friedlander, M. Leonard, “Baseline predictors of early treatment failure in patients with platinum resistant/refractory (PRR) and potentially platinum sensitive (PPS ≥ 3) recurrent ovarian cancer (ROC) receiving ≥ 3 lines of chemotherapy: The GCIG Symptom Benefit Study (SBS).”. 2015.

E. Despierre, Vergote, I. B., Anderson, R., Coens, C., Katsaros, D., Hirsch, F. R., Boeckx, B., Varella-Garcia, M., Ferrero, A., Ray-Coquard, I., Berns, E. M. J. J., Casado, A., Lambrechts, D., and Jimeno, A., “Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy.”, Target Oncol, vol. 10, no. 4, pp. 583-96, 2015.PubMed

D. K. Gaffney, Suneja, G., Ryu, S. Young, McCormick, M., Plante, M., Mileshkin, L. R., Small, W., Bacon, M., Stuart, G. C. E., and Kitchener, H. C., “The Cervix Cancer Research Network: A Global Outreach Effort on Behalf of the Gynecologic Cancer InterGroup.”, Int J Radiat Oncol Biol Phys, vol. 92, no. 3, pp. 506-8, 2015.PubMed

R. T. Penson, Huang, H. Q., Wenzel, L. B., Monk, B. J., Stockman, S., Long, H. J., Ramondetta, L. M., Landrum, L. M., Oaknin, A., Reid, T. J. A., Leitao, M. M., Method, M., Michael, H., and Tewari, K. S., “Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240).”, Lancet Oncol, vol. 16, no. 3, pp. 301-11, 2015.PubMed DOI

T. Iwata, Hasegawa, T., Ochiai, K., Takizawa, K., Umezawa, S., Kuramoto, H., Ohmura, M., Kubushiro, K., Arai, H., Sakamoto, M., Motoyama, T., Watanabe, K., and Aoki, D., “Human Papillomavirus Test for Triage of Japanese Women With Low-Grade Squamous Intraepithelial Lesions.”, Reprod Sci, vol. 22, no. 12, pp. 1509-15, 2015.PubMed

M. E. Abdel-Rahman, Butler, J., Sydes, M. R., Parmar, M. K. B., Gordon, E., Harper, P., Williams, C., Crook, A., Sandercock, J., Swart, A. Marie, Rachet, B., and Coleman, M. P., “No socioeconomic inequalities in ovarian cancer survival within two randomised clinical trials”, Br J Cancer, vol. 111, pp. 589-97, 2014.Google Scholar

G. Emons, Gorchev, G., Sehouli, J., Wimberger, P., Stähle, A., Hanker, L., Hilpert, F., Sindermann, H., Grundker, C., and Harter, P., “Efficacy and safety of AEZS-108 (INN: zoptarelin doxorubicin acetate) an LHRH agonist linked to doxorubicin in women with platinum refractory or resistant ovarian cancer expressing LHRH receptors: a multicenter phase II trial of the AGO-study group (AGO G”, Gynecol Oncol, vol. 133, pp. 427-32, 2014.Google Scholar

M. Leonard Friedlander, Stockler, M., O'Connell, R., Voysey, M., Oza, A. M., Gillies, K., Donovan, H., Martyn, J., Sjoquist, K. Marie, Butow, P., King, M. Trudy, and Group, S. Benefit St, “Symptom burden and outcomes of patients with platinum resistant/refractory recurrent ovarian cancer: a reality check: results of stage 1 of the Gynecologic Cancer Intergroup symptom benefit study”, Int J Gynecol Cancer, vol. 24, pp. 857-64, 2014.Google Scholar

R. M. Glasspool, Brown, R., Gore, M. E., Rustin, G. J. S., McNeish, I. A., Wilson, R. H., Pledge, S., Paul, J., Mackean, M., Hall, G. D., Gabra, H., Halford, S. E., Walker, J. L., Appleton, K., Ullah, R., Kaye, S. B., and Group, S. Gynaecolog, “A randomised, phase II trial of the DNA-hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in combination with carboplatin vs carboplatin alone in patients with recurrent, partially platinum-sensitive ovarian cancer”, Br J Cancer, vol. 110, pp. 1923-9, 2014.Google Scholar

M. Mikami, Aoki, Y., Sakamoto, M., Shimada, M., Takeshima, N., Fujiwara, H., Matsumoto, T., Kita, T., Takizawa, K., Cervical, D. Committee, and Group, V. Cancer Jap, “Surgical Principles for Managing Stage IB2, IIA2, and IIB Uterine Cervical Cancer (Bulky Tumors) in Japan: A Survey of the Japanese Gynecologic Oncology Group”, Int J Gynecol Cancer, 2014.Google Scholar

M. Okadome, Saito, T., Tanaka, H., Nogawa, T., Furuta, R., Watanabe, K., Kita, T., Yamamoto, K., Mikami, M., Takizawa, K., and Group, J. Gynecologi, “Potential impact of combined high- and low-risk human papillomavirus infection on the progression of cervical intraepithelial neoplasia 2”, J Obstet Gynaecol Res, vol. 40, pp. 561-9, 2014.Google Scholar

S. Pignata, Scambia, G., Katsaros, D., Gallo, C., Pujade-Lauraine, E., De Placido, S., Bologna, A., Weber, B., Raspagliesi, F., Panici, P. B., Cormio, G., Sorio, R., Cavazzini, M. G., Ferrandina, G., Breda, E., Murgia, V., Sacco, C., Cinieri, S., Salutari, V., Ricci, C., Pisano, C., Greggi, S., Lauria, R., Lorusso, D., Marchetti, C., Selvaggi, L., Signoriello, S., Piccirillo, M. C., Di Maio, M., Perrone, F., Cancer, M. Italian Tr, Sein, Gd'Investig, Oncology, M. Negri Gyne, Groups, E. Network of, and Investigators, G. Cancer Int, “Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial”, Lancet Oncol, vol. 15, pp. 396-405, 2014.Google Scholar

F. Trillsch, Mahner, S., Woelber, L., Vettorazzi, E., Reuss, A., Ewald-Riegler, N., de Gregorio, N., Fotopoulou, C., Schmalfeldt, B., Burges, A., Hilpert, F., Fehm, T., Meier, W., Hillemanns, P., Hanker, L., Hasenburg, A., Strauss, H. G., Hellriegel, M., Wimberger, P., Baumann, K. H., Keyver-Paik, M. D., Canzler, U., Wollschlaeger, K., Forner, D., Pfisterer, J., Schröder, W., Muenstedt, K., Richter, B., Kommoss, F., Hauptmann, S., and du Bois, A., “Age-dependent differences in borderline ovarian tumours (BOT) regarding clinical characteristics and outcome: Results from a sub-analysis of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) ROBOT study”, Ann Oncol, vol. 25, pp. 1320-7, 2014.Google Scholar

D. Trudel, Desmeules, P., Turcotte, S., Plante, M., Gregoire, J., Renaud, M. C., Orain, M., Bairati, I., and Tetu, B., “Visual and automated assessment of matrix metalloproteinase-14 tissue expression for the evaluation of ovarian cancer prognosis”, Mod Pathol, 2014.Google Scholar

I. B. Vergote, Jimeno, A., Joly, F., Katsaros, D., Coens, C., Despierre, E., Marth, C., Hall, M., Steer, C. B., Colombo, N., Lesoin, A., Casado, A., Reinthaller, A., Green, J. A., Buck, M., Ray-Coquard, I., Ferrero, A., Favier, L., Reed, N. Simon, Curé, H., and Pujade-Lauraine, E., “Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: a EORTC GCG, and GCIG study.”, J Clin Oncol, vol. 32, no. 4, pp. 320-6, 2014.PubMed

A. du Bois, Floquet, A., Kim, J. - W., Rau, J., Del Campo, J. M., Friedlander, M. Leonard, Pignata, S., Fujiwara, K., Vergote, I. B., Colombo, N., Mirza, M. R., Monk, B. J., Kimmig, R., Ray-Coquard, I., Zang, R., Diaz-Padilla, I., Baumann, K. H., Mouret-Reynier, M. - A., Kim, J. - H., Kurzeder, C., Lesoin, A., Vasey, P. A., Marth, C., Canzler, U., Scambia, G., Shimada, M., Calvert, P., Pujade-Lauraine, E., Kim, B. - G., Herzog, T. J., Mitrica, I., Schade-Brittinger, C., Wang, Q., Crescenzo, R. J., and Harter, P., “Incorporation of pazopanib in maintenance therapy of ovarian cancer.”, J Clin Oncol, vol. 32, no. 30, p. 3382, 2014.PubMed

J. Martyn, Stonebraker, B., Carty, K., Bryce, J., and Bacon, M., “International Harmonization of Ovarian Cancer Patient’s Tumor Assessments: A Gynecologic Cancer Intergroup (GCIG) Survey.”. 2014.Google Scholar

E. Pujade-Lauraine, Hilpert, F., Weber, B., Reuss, A., Poveda, A. M., Kristensen, G. B., Sorio, R., Vergote, I. B., Witteveen, P., Bamias, A., Pereira, D., Wimberger, P., Oaknin, A., Mirza, M. Raza, Follana, P., Bollag, D., and Ray-Coquard, I., “Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial.”, J Clin Oncol, vol. 32, no. 13, p. 1308, 2014.PubMed

M. R. Stockler, Hilpert, F., Friedlander, M. Leonard, King, M. Trudy, Wenzel, L. B., Lee, C. Khoon, Joly, F., de Gregorio, N., Arranz, J. Angel, Mirza, M. Raza, Sorio, R., Freudensprung, U., Sneller, V., Hales, G., and Pujade-Lauraine, E., “Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer.”, J Clin Oncol, vol. 32, no. 13, p. 1316, 2014.PubMed

P. Harter, Gershenson, D., Lhomme, C., Lecuru, F., Ledermann, J. A., Provencher, D. M., Mezzanzanica, D., Quinn, M., Maenpaa, J. U., Kim, J. - W., Mahner, S., Hilpert, F., Baumann, K. H., Pfisterer, J., and du Bois, A., “Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian tumors of low malignant potential (borderline ovarian tumors).”, Int J Gynecol Cancer, vol. 24, no. 9 Suppl 3, pp. S5-8, 2014.PubMed

C. Gourley, Farley, J., Provencher, D. M., Pignata, S., Mileshkin, L. R., Harter, P., Maenpaa, J. U., Kim, J. - W., Pujade-Lauraine, E., Glasspool, R. M., Ray-Coquard, I., and Gershenson, D., “Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian and primary peritoneal low-grade serous carcinomas.”, Int J Gynecol Cancer, vol. 24, no. 9 Suppl 3, pp. S9-13, 2014.PubMed

. A. Ledermann, Luvero, D., Shafer, A., O'Connor, D., Mangili, G., Friedlander, M. Leonard, Pfisterer, J., Mirza, M. R., Kim, J. - W., Alexandre, J., Oza, A. M., and Brown, J., “Gynecologic Cancer InterGroup (GCIG) consensus review for mucinous ovarian carcinoma.”, Int J Gynecol Cancer, vol. 24, no. 9 Suppl 3, pp. S14-9, 2014.PubMed

A. Okamoto, Glasspool, R. M., Mabuchi, S., Matsumura, N., Nomura, H., Itamochi, H., Takano, M., Takano, T., Susumu, N., Aoki, D., Konishi, I., Covens, A., Ledermann, J. A., Mezzanzanica, D., Mezzazanica, D., Steer, C., Millan, D., McNeish, I. A., Pfisterer, J., Kang, S., Gladieff, L., Bryce, J., and Oza, A. M., “Gynecologic Cancer InterGroup (GCIG) consensus review for clear cell carcinoma of the ovary.”, Int J Gynecol Cancer, vol. 24, no. 9 Suppl 3, pp. S20-5, 2014.PubMed

. M. Glasspool, Martín, A. González, Millan, D., Lorusso, D., Åvall-Lundqvist, E., Hurteau, J. A., Davis, A., Hilpert, F., Kim, J. - W., Alexandre, J., and Ledermann, J. A., “Gynecologic Cancer InterGroup (GCIG) consensus review for squamous cell carcinoma of the ovary.”, Int J Gynecol Cancer, vol. 24, no. 9 Suppl 3, pp. S26-9, 2014.PubMed

N. Simon Reed, Pautier, P., Åvall-Lundqvist, E., Choi, C. - H., du Bois, A., Friedlander, M. Leonard, Fyles, A., Kichenadasse, G., Provencher, D. M., and Ray-Coquard, I., “Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian small cell cancers.”, Int J Gynecol Cancer, vol. 24, no. 9 Suppl 3, pp. S30-4, 2014.PubMed

N. Simon Reed, Gomez-Garcia, E., Gallardo-Rincon, D., Barrette, B. A., Baumann, K. H., Friedlander, M. Leonard, Kichenadasse, G., Kim, J. - W., Lorusso, D., Mirza, M. Raza, and Ray-Coquard, I., “Gynecologic Cancer InterGroup (GCIG) consensus review for carcinoid tumors of the ovary.”, Int J Gynecol Cancer, vol. 24, no. 9 Suppl 3, pp. S35-41, 2014.PubMed

I. Ray-Coquard, Brown, J., Harter, P., Provencher, D. M., Fong, P. C., Maenpaa, J. U., Ledermann, J. A., Emons, G., Rigaud, D. Berton, Glasspool, R. M., Mezzanzanica, D., and Colombo, N., “Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian sex cord stromal tumors.”, Int J Gynecol Cancer, vol. 24, no. 9 Suppl 3, pp. S42-7, 2014.PubMed

J. Brown, Friedlander, M. Leonard, Backes, F. J., Harter, P., O'Connor, D. M., Rouge, Tde la Mott, Lorusso, D., Maenpaa, J. U., Kim, J. - W., Tenney, M. E., and Seckl, M. J., “Gynecologic Cancer Intergroup (GCIG) consensus review for ovarian germ cell tumors.”, Int J Gynecol Cancer, vol. 24, no. 9 Suppl 3, pp. S48-54, 2014.PubMed

D. Berton-Rigaud, Devouassoux-Shisheboran, M., Ledermann, J. A., Leitao, M. M., Powell, M. A., Poveda, A. M., Beale, P., Glasspool, R. M., Creutzberg, C. L., Harter, P., Kim, J. - W., Reed, N. Simon, and Ray-Coquard, I., “Gynecologic Cancer InterGroup (GCIG) consensus review for uterine and ovarian carcinosarcoma.”, Int J Gynecol Cancer, vol. 24, no. 9 Suppl 3, pp. S55-60, 2014.PubMed

M. L. Hensley, Barrette, B. A., Baumann, K. H., Gaffney, D. K., Hamilton, A. L., Kim, J. - W., Maenpaa, J. U., Pautier, P., Siddiqui, N. Ahmad, Westermann, A. M., and Ray-Coquard, I., “Gynecologic Cancer InterGroup (GCIG) consensus review: uterine and ovarian leiomyosarcomas.”, Int J Gynecol Cancer, vol. 24, no. 9 Suppl 3, pp. S61-6, 2014.PubMed

F. Amant, Floquet, A., Friedlander, M. Leonard, Kristensen, G. B., Mahner, S., Nam, E. Ji, Powell, M. A., Ray-Coquard, I., Siddiqui, N. Ahmad, Sykes, P., Westermann, A. M., and Seddon, B., “Gynecologic Cancer InterGroup (GCIG) consensus review for endometrial stromal sarcoma.”, Int J Gynecol Cancer, vol. 24, no. 9 Suppl 3, pp. S67-72, 2014.PubMed

P. Pautier, Nam, E. Ji, Provencher, D. M., Hamilton, A. L., Mangili, G., Siddiqui, N. Ahmad, Westermann, A. M., Reed, N. Simon, Harter, P., and Ray-Coquard, I., “Gynecologic Cancer InterGroup (GCIG) consensus review for high-grade undifferentiated sarcomas of the uterus.”, Int J Gynecol Cancer, vol. 24, no. 9 Suppl 3, pp. S73-7, 2014.PubMed

M. Leonard Friedlander, Covens, A., Glasspool, R. M., Hilpert, F., Kristensen, G. B., Kwon, S., Selle, F., Small, W., Witteveen, E., and Russell, P., “Gynecologic Cancer InterGroup (GCIG) consensus review for mullerian adenosarcoma of the female genital tract.”, Int J Gynecol Cancer, vol. 24, no. 9 Suppl 3, pp. S78-82, 2014.PubMed

S. Sagae, Susumu, N., Viswanathan, A., Aoki, D., Backes, F. J., Provencher, D. M., Vaughan, M., Creutzberg, C. L., Kurzeder, C., Kristensen, G. B., Lee, C., Kurtz, J. - E., Glasspool, R. M., and Small, W., “Gynecologic Cancer InterGroup (GCIG) consensus review for uterine serous carcinoma.”, Int J Gynecol Cancer, vol. 24, no. 9 Suppl 3, pp. S83-9, 2014.PubMed

K. Hasegawa, Nagao, S., Yasuda, M., Millan, D., Viswanathan, A., Glasspool, R. M., Devouassoux-Shisheboran, M., Covens, A., Lorusso, D., Kurzeder, C., Kim, J. - W., Gladieff, L., Bryce, J., Friedlander, M. Leonard, and Fujiwara, K., “Gynecologic Cancer InterGroup (GCIG) consensus review for clear cell carcinoma of the uterine corpus and cervix.”, Int J Gynecol Cancer, vol. 24, no. 9 Suppl 3, pp. S90-5, 2014.PubMed

H. Fujiwara, Yokota, H., Monk, B. J., Treilleux, I., Devouassoux-Shisheboran, M., Davis, A., Kim, J. - W., Mahner, S., Stany, M., Pignata, S., Ray-Coquard, I., and Fujiwara, K., “Gynecologic Cancer InterGroup (GCIG) consensus review for cervical adenocarcinoma.”, Int J Gynecol Cancer, vol. 24, no. 9 Suppl 3, pp. S96-101, 2014.PubMed

T. Satoh, Takei, Y., Treilleux, I., Devouassoux-Shisheboran, M., Ledermann, J. A., Viswanathan, A., Mahner, S., Provencher, D. M., Mileshkin, L. R., Åvall-Lundqvist, E., Pautier, P., Reed, N. Simon, and Fujiwara, K., “Gynecologic Cancer InterGroup (GCIG) consensus review for small cell carcinoma of the cervix.”, Int J Gynecol Cancer, vol. 24, no. 9 Suppl 3, pp. S102-8, 2014.PubMed

M. M. Leitao, Cheng, X., Hamilton, A. L., Siddiqui, N. Ahmad, Jürgenliemk-Schulz, I. M., Mahner, S., Åvall-Lundqvist, E., Kim, K., and Freyer, G., “Gynecologic Cancer InterGroup (GCIG) consensus review for vulvovaginal melanomas.”, Int J Gynecol Cancer, vol. 24, no. 9 Suppl 3, pp. S117-22, 2014.PubMed

G. Mangili, Lorusso, D., Brown, J., Pfisterer, J., Massuger, L., Vaughan, M., Ngan, H. Y. S., Golfier, F., Sekharan, P. K., Charry, R. Cortés, Poveda, A. M., Kim, J. - W., Xiang, Y., Berkowtiz, R., and Seckl, M. J., “Trophoblastic disease review for diagnosis and management: a joint report from the International Society for the Study of Trophoblastic Disease, European Organisation for the Treatment of Trophoblastic Disease, and the Gynecologic Cancer InterGroup.”, Int J Gynecol Cancer, vol. 24, no. 9 Suppl 3, pp. S109-16, 2014.PubMed

F. Collinson, Qian, W., Fossati, R., Lissoni, A., Williams, C., Parmar, M. K. B., Ledermann, J. A., Colombo, N., and Swart, A. Marie, “Optimal treatment of early-stage ovarian cancer.”, Ann Oncol, vol. 25, no. 6, pp. 1165-71, 2014.PubMed

J. A. Ledermann and Ray-Coquard, I., “Novel approaches to improve the treatment of rare gynecologic cancers: research opportunities and challenges.”, Am Soc Clin Oncol Educ Book, pp. e282-6, 2014.PubMed

K. S. Tewari, Sill, M. W., Long, H. J., Penson, R. T., Huang, H., Ramondetta, L. M., Landrum, L. M., Oaknin, A., Reid, T. J., Leitao, M. M., Michael, H. E., and Monk, B. J., “Improved survival with bevacizumab in advanced cervical cancer.”, N Engl J Med, vol. 370, no. 8, pp. 734-43, 2014.PubMed

T. Sugiyama, Fujiwara, K., Ohashi, Y., Yokota, H., Hatae, M., Ohno, T., Nagai, Y., Mitsuhashi, N., Ochiai, K., and Noda, K., “Phase III placebo-controlled double-blind randomized trial of radiotherapy for stage IIB-IVA cervical cancer with or without immunomodulator Z-100: a JGOG study.”, Ann Oncol, vol. 25, no. 5, pp. 1011-7, 2014.PubMed

J. Ang, Gourley, C., Powell, C., High, H., Shapira-Frommer, R., Castonguay, V., De Greve, J., Atkinson, T., Yap, T. A., Sandhu, S., Banerjee, S., Chen, L., Friedlander, M. Leonard, Kaufman, B., Oza, A. M., Matulonis, U., Barber, L., Kozarewa, I., Fenwick, K., Assiotis, I., Campbell, J., Chen, L., de Bono, J., Gore, M. E., Lord, C., Ashworth, A., and Kaye, S. B., “Efficacy of chemotherapy in BRCA1/2 mutation carrier ovarian cancer in the setting of PARP inhibitor resistance: a multi-institutional study”, Clin Cancer Res, vol. 19, pp. 5485-93, 2013.Google Scholar 

C. L. Creutzberg, Kitchener, H. C., Birrer, M. J., Landoni, F., Lu, K. H., Powell, M., Aghajanian, C., Edmondson, R., Goodfellow, P. J., Quinn, M., Salvesen, H. B., Thomas, G., and Meeting, G. C. I. G. Endometria, “Gynecologic Cancer InterGroup (GCIG) Endometrial Cancer Clinical Trials Planning Meeting: taking endometrial cancer trials into the translational era”, Int J Gynecol Cancer, vol. 23, pp. 1528-34, 2013.Google Scholar 

G. Emile, Chauvenet, L., Tigaud, J. M., Chidiac, J., E. Lauraine, P., and Alexandre, J., “A clinical experience of single agent bevacizumab in relapsing ovarian cancer”, Gynecol Oncol, vol. 129, pp. 459-62, 2013.Google Scholar 

G. A. Martin, Redondo, A., Jurado, M., De Juan, A., Romero, I., Bover, I., Del Campo, J. M., Cervantes, A., Garcia, Y., Lopez-Guerrero, J. A., Mendiola, C., Palacios, J., Rubio, M. J., and A. Velasco, P., “GEICO (Spanish Group for Investigation on Ovarian Cancer) treatment guidelines in ovarian cancer 2012”, Clin Transl Oncol, vol. 15, pp. 509-25, 2013.Google Scholar 

D. Handolias, Quinn, M., Foo, S., Mileshkin, L. R., Grant, P., Dutu, G., and Rischin, D., “Oral cyclophosphamide in recurrent ovarian cancer”, Asia Pac J Clin Oncol, 2013.Google Scholar 

N. Katsumata, Yasuda, M., Isonishi, S., Takahashi, F., Michimae, H., Kimura, E., Aoki, D., Jobo, T., Kodama, S., Terauchi, F., Sugiyama, T., Ochiai, K., and Group, J. Gynecologi, “Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial”, Lancet Oncol, vol. 14, pp. 1020-6, 2013.Google Scholar 

J. F. Liu, Tolaney, S. M., Birrer, M. J., Fleming, G. F., Buss, M. K., Dahlberg, S. E., Lee, H., Whalen, C., Tyburski, K., Winer, E., Ivy, P., and Matulonis, U. A., “A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer”, Eur J Cancer, vol. 49, pp. 2972-8, 2013.Google Scholar 

M. Mikami, Aoki, Y., Sakamoto, M., Shimada, M., Takeshima, N., Fujiwara, H., Matsumoto, T., Kita, T., Takizawa, K., Cervical, D. Committee, and Group, V. Cancer Jap, “Current surgical principle for uterine cervical cancer of stages Ia2, Ib1, and IIa1 in Japan: a survey of the Japanese Gynecologic Oncology Group”, Int J Gynecol Cancer, vol. 23, pp. 1655-60; quiz 1661-2, 2013.Google Scholar 

D. Shaw, Clamp, A. R., and Jayson, G. C., “Angiogenesis as a target for the treatment of ovarian cancer”, Curr Opin Oncol, vol. 25, pp. 558-65, 2013.Google Scholar 

K. D. Steffensen, Waldstrom, M., Pallisgard, N., Lund, B., Bergfeldt, K., Wihl, J., Keldsen, N., Marth, C., Vergote, I. B., and Jakobsen, A., “Panitumumab and pegylated liposomal doxorubicin in platinum-resistant epithelial ovarian cancer with KRAS wild-type: the PaLiDo study, a phase II nonrandomized multicenter study”, Int J Gynecol Cancer, vol. 23, pp. 73-80, 2013.Google Scholar 

B. Weber, Largillier, R., Ray-Coquard, I., Yazbek, G., Meunier, J., Alexandre, J., Dauba, J., Spaeth, D., Delva, R., Joly, F., Pujade-Lauraine, E., Copel, L., and France, G. I. N. E. C. O. Group, “A potentially neuroprotective role for erythropoietin with paclitaxel treatment in ovarian cancer patients: a prospective phase II GINECO trial”, Support Care Cancer, vol. 21, pp. 1947-54, 2013.Google Scholar 

S. Banerjee, Rustin, G. J. S., Paul, J., Williams, C., Pledge, S., Gabra, H., Skailes, G., Lamont, A., Hindley, A., Goss, G., Gilby, E., Hogg, M., Harper, P., Kipps, E., Lewsley, L. A., Hall, M., Vasey, P. A., and Kaye, S. B., “A multicenter, randomized trial of flat dosing versus intrapatient dose escalation of single-agent carboplatin as first-line chemotherapy for advanced ovarian cancer: an SGCTG (SCOTROC 4) and ANZGOG study on behalf of GCIG.”, Ann Oncol, vol. 24, no. 3, p. 687, 2013.PubMed 

B. J. Monk, Pujade-Lauraine, E., and Burger, R. A., “Integrating bevacizumab into the management of epithelial ovarian cancer: the controversy of front-line versus recurrent disease.”, Ann Oncol, vol. 24 Suppl 10, p. x58, 2013.PubMed 

B. You, Colomban, O., Heywood, M., Lee, C., Davy, M., Reed, N. Simon, Pignata, S., Varsellona, N., Emons, G., Rehman, K., Steffensen, K. Dahl, Reinthaller, A., Pujade-Lauraine, E., and Oza, A. M., “The strong prognostic value of KELIM, a model-based parameter from CA 125 kinetics in ovarian cancer: data from CALYPSO trial (a GINECO-GCIG study).”, Gynecol Oncol, vol. 130, no. 2, p. 294, 2013.PubMed 

C. Khoon Lee, Simes, R. J., Brown, C., Gebski, V., Pfisterer, J., Swart, A. Marie, Berton-Rigaud, D., Plante, M., Skeie-Jensen, T., Vergote, I. B., Schauer, C., Pisano, C., Parma, G., Baumann, K. H., Ledermann, J. A., Pujade-Lauraine, E., Bentley, J., Kristensen, G. B., Belau, A., Nankivell, M., Canzler, U., Lord, S. J., Kurzeder, C., and Friedlander, M. Leonard, “A prognostic nomogram to predict overall survival in patients with platinum-sensitive recurrent ovarian cancer.”, Ann Oncol, vol. 24, no. 4, p. 943, 2013.PubMed 

D. Stark, Nankivell, M., Pujade-Lauraine, E., Kristensen, G. B., Elit, L., Stockler, M., Hilpert, F., Cervantes, A., Brown, J., Lanceley, A., Velikova, G., Sabate, E., Pfisterer, J., Carey, M. S., Beale, P., Qian, W., Swart, A. Marie, Oza, A. M., and Perren, T. J., “Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial.”, Lancet Oncol, vol. 14, no. 3, p. 243, 2013.PubMed 

E. Greimel, Kristensen, G. B., van der Burg, M. E. L., Coronado, P., Rustin, G. J. S., del Rio, A. Sanchez, Reed, N. Simon, Nordal, R. R., Coens, C., and Vergote, I. B., “Quality of life of advanced ovarian cancer patients in the randomized phase III study comparing primary debulking surgery versus neo-adjuvant chemotherapy.”, Gynecol Oncol, vol. 131, no. 2, pp. 437-44, 2013.PubMed

F. Heitz, du Bois, A., Harter, P., Lubbe, D., Kurzeder, C., Vergote, I. B., Plante, M., and Pfisterer, J., “Impact of beta blocker medication in patients with platinum sensitive recurrent ovarian cancer-a combined analysis of 2 prospective multicenter trials by the AGO Study Group, NCIC-CTG and EORTC-GCG.”, Gynecol Oncol, vol. 129, no. 3, pp. 463-6, 2013.PubMed

F. A. Raja, Counsell, N., Colombo, N., Pfisterer, J., du Bois, A., Parmar, M. K. B., Vergote, I. B., Gonzalez-Martin, A., Alberts, D. S., Plante, M., Torri, V., and Ledermann, J. A., “Platinum versus platinum-combination chemotherapy in platinum-sensitive recurrent ovarian cancer: a meta-analysis using individual patient data.”, Ann Oncol, vol. 24, no. 12, pp. 3028-34, 2013.PubMed 

K. Ushijima, Kamura, T., Tamura, K., Kuzuya, K., Sugiyama, T., Noda, K., and Ochiai, K., “Docetaxel/irinotecan combination chemotherapy in platinum/taxane-refractory and -resistant ovarian cancer: JGOG/WJGOG Intergroup Study.”, Int J Clin Oncol, vol. 18, no. 1, pp. 126-31, 2013.PubMed

D. ' T. Anna, Signorelli, M., Benedetti-Panici, P., Maggioni, A., Fossati, R., Fruscio, R., Milani, R., Bocciolone, L., Buda, A., Mangioni, C., Scambia, G., Angioli, R., Campagnutta, E., Grassi, R., and Landoni, F., “Systematic lymphadenectomy in ovarian cancer at second-look surgery: a randomised clinical trial”, Br J Cancer, vol. 107, pp. 785-92, 2012.Google Scholar 

L. C. Hanker, Loibl, S., Burchardi, N., Pfisterer, J., Meier, W., Pujade-Lauraine, E., Ray-Coquard, I., Sehouli, J., Harter, P., du Bois, A., ,, and Group, G. I. N. E. C. O. Study, “The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy”, Ann Oncol, vol. 23, pp. 2605-12, 2012.Google Scholar 

J. - E. Kurtz, Freyer, G., Joly, F., Gladieff, L., Kaminsky, M. C., Fabbro, M., Floquet, A., Hardy-Bessard, A. C., Raban, N., Ray-Coquard, I., Pujade-Lauraine, E., and France, G. I. N. E. C. O. Group, “Combined oral topotecan plus carboplatin in relapsed or advanced cervical cancer: a GINECO phase I-II trial”, Anticancer Res, vol. 32, pp. 1045-9, 2012.Google Scholar 

A. Lortholary, Largillier, R., Weber, B., Gladieff, L., Alexandre, J., Durando, X., Slama, B., Dauba, J., Paraiso, D., Pujade-Lauraine, E., and France, G. I. N. E. C. O. Group, “Weekly paclitaxel as a single agent or in combination with carboplatin or weekly topotecan in patients with resistant ovarian cancer: the CARTAXHY randomized phase II trial from Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO)”, Ann Oncol, vol. 23, pp. 346-52, 2012.Google Scholar 

C. V. Madsen, Steffensen, K. D., Olsen, D. A., Waldstrom, M., Smerdel, M., Adimi, P., Brandslund, I., and Jakobsen, A., “Serial measurements of serum PDGF-AA, PDGF-BB, FGF2, and VEGF in multiresistant ovarian cancer patients treated with bevacizumab”, J Ovarian Res, vol. 5, p. 23, 2012.Google Scholar 

L. M. Randall, Sill, M. W., Burger, R. A., Monk, B. J., Buening, B., and Sorosky, J. I., “Predictive value of serum CA-125 levels in patients with persistent or recurrent epithelial ovarian cancer or peritoneal cancer treated with bevacizumab on a Gynecologic Oncology Group phase II trial”, Gynecol Oncol, vol. 124, pp. 563-8, 2012.Google Scholar 

S. Sagae, Aoki, D., Susumu, N., Okamoto, A., Aotani, E., Takeuchi, M., and Mandai, M., “[Current movement in global clinical trials–discussion at Gynecologic Cancer Intergroup (GCIG)]”, Nihon Rinsho, vol. 70 Suppl 4, pp. 59-66, 2012.Google Scholar 

T. Toita, Kitagawa, R., Hamano, T., Umayahara, K., Hirashima, Y., Aoki, Y., Oguchi, M., Mikami, M., Takizawa, K., and Group, C. Cancer Com, “Phase II study of concurrent chemoradiotherapy with high-dose-rate intracavitary brachytherapy in patients with locally advanced uterine cervical cancer: efficacy and toxicity of a low cumulative radiation dose schedule”, Gynecol Oncol, vol. 126, pp. 211-6, 2012.Google Scholar 

T. Toita, Kitagawa, R., Hamano, T., Umayahara, K., Hirashima, Y., Aoki, Y., Oguchi, M., Mikami, M., Takizawa, K., and Group, C. Cancer Vul, “Feasibility and acute toxicity of Concurrent Chemoradiotherapy (CCRT) with high-dose rate intracavitary brachytherapy (HDR-ICBT) and 40-mg/m2 weekly cisplatin for Japanese patients with cervical cancer: results of a Multi-Institutional Phase 2 Study (JGOG”, Int J Gynecol Cancer, vol. 22, pp. 1420-6, 2012.Google Scholar 

A. Casado, Penninckx, B., Reed, N. Simon, van der Burg, M. E. L., Berns, E. M. J. J., Katsaros, D., Ferrero, A., Fernando, M., Jimeno, A., Vermorken, J. B., Pecorelli, S., and Vergote, I. B., “EORTC Gynecological Cancer Group on the frontline of practice-changing clinical trials. ”, European Journal Cancer , vol. 10, no. 1, p. 73, 2012.DOI 

R. Lindsay, Paul, J., Siddiqui, N. Ahmad, Davis, J., and Gaffney, D. K., “Survey on the management of early cervical cancer among members of the GCIG.”, Int J Gynecol Cancer, vol. 22, no. 9, p. 1623, 2012.PubMed 

U. Wagner, Marth, C., Largillier, R., Kaern, J., Brown, C., Heywood, M., Bonaventura, T., Vergote, I. B., Piccirillo, M. C., Fossati, R., Gebski, V., and Lauraine, E. P., “Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients.”, Br J Cancer, vol. 107, no. 4, p. 591, 2012.PubMed 

J. Alexandre, Brown, C., Coeffic, D., Raban, N., Pfisterer, J., Maenpaa, J. U., Chalchal, H., Fitzharris, B., Volgger, B., Vergote, I. B., Pisano, C., Ferrero, A., and Pujade-Lauraine, E., “CA-125 can be part of the tumour evaluation criteria in ovarian cancer trials: experience of the GCIG CALYPSO trial.”, Br J Cancer, vol. 106, no. 4, p. 637, 2012.PubMed 

M. Brundage, Gropp, M., Mefti, F., Mann, K., Lund, B., Gebski, V., Wolfram, G., Reed, N. Simon, Pignata, S., Ferrero, A., Brown, C., Eisenhauer, E., and Pujade-Lauraine, E., “Health-related quality of life in recurrent platinum-sensitive ovarian cancer--results from the CALYPSO trial.”, Ann Oncol, vol. 23, no. 8, p. 2027, 2012.PubMed 

K. Lindemann, Christensen, R. D., Vergote, I. B., Stuart, G. C. E., Izquierdo, M. A., Kærn, J., Havsteen, H., Eisenhauer, E., Ridderheim, M., Lopez, A. B., Hirte, H., Åvall-Lundqvist, E., Vrdoljak, E., Green, J. A., and Kristensen, G. B., “First-line treatment of advanced ovarian cancer with paclitaxel/carboplatin with or without epirubicin (TEC versus TC)--a gynecologic cancer intergroup study of the NSGO, EORTC GCG and NCIC CTG.”, Ann Oncol, vol. 23, no. 10, pp. 2613-9, 2012.PubMed 

L. Gladieff, Ferrero, A., De Rauglaudre, G., Brown, C., Vasey, P. A., Reinthaller, A., Pujade-Lauraine, E., Reed, N. Simon, Lorusso, D., Siena, S., Helland, H., Elit, L., and Mahner, S., “Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in partially platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial.”, Ann Oncol, vol. 23, no. 5, pp. 1185-9, 2012.PubMed 

E. L. Trimble, Ledermann, J. A., Law, K., Miyata, T., Imamura, C. K., Nam, B. - H., Kim, Y. H., Bang, Y. - J., Michaels, M., Ardron, D., Amano, S., Ando, Y., Tominaga, T., Kurokawa, K., and Takebe, N., “International models of investigator-initiated trials: implications for Japan.”, Ann Oncol, vol. 23, no. 12, pp. 3151-5, 2012.PubMed DOI 

A. Viswanathan, Creutzberg, C. L., Craighead, P., McCormack, M., Toita, T., Narayan, K., Reed, N. Simon, Long, H. J., Kim, H. - J., Marth, C., Lindegaard, J. C., Cerrotta, A., Small, W., and Trimble, E. L., “International brachytherapy practice patterns: a survey of the Gynecologic Cancer Intergroup (GCIG).”, Int J Radiat Oncol Biol Phys, vol. 82, no. 1, pp. 250-5, 2012.PubMed 

S. Yamaguchi, Nishimura, R., Yaegashi, N., Kiguchi, K., Sugiyama, T., Kita, T., Kubushiro, K., Kokawa, K., Hiura, M., Mizutani, K., Yamamoto, K., and Takizawa, K., “Phase II study of neoadjuvant chemotherapy with irinotecan hydrochloride and nedaplatin followed by radical hysterectomy for bulky stage Ib2 to IIb, cervical squamous cell carcinoma: Japanese Gynecologic Oncology Group study (JGOG 1065).”, Oncol Rep, vol. 28, no. 2, pp. 487-93, 2012.PubMed

E. Greimel, Bjelic-Radisic, V., Pfisterer, J., Hilpert, F., Daghofer, F., Pujade-Lauraine, E., du Bois, A., Group, A. Gynaekolog, and de l'Ovaire, Gd'Investig, “Toxicity and quality of life outcomes in ovarian cancer patients participating in randomized controlled trials”, Support Care Cancer, vol. 19, pp. 1421-7, 2011.Google Scholar 

K. Kudoh, Takano, M., Kouta, H., Kikuchi, R., Kita, T., Miyamoto, M., Watanabe, A., Kato, M., Goto, T., and Kikuchi, Y., “Effects of bevacizumab and pegylated liposomal doxorubicin for the patients with recurrent or refractory ovarian cancers”, Gynecol Oncol, vol. 122, pp. 233-7, 2011.Google Scholar 

S. Pignata, Scambia, G., Ferrandina, G., Savarese, A., Sorio, R., Breda, E., Gebbia, V., Musso, P., Frigerio, L., Del Medico, P., Lombardi, A. V., Febbraro, A., Scollo, P., Ferro, A., Tamberi, S., Brandes, A., Ravaioli, A., Valerio, M. R., Aitini, E., Natale, D., Scaltriti, L., Greggi, S., Pisano, C., Lorusso, D., Salutari, V., Legge, F., Di Maio, M., Morabito, A., Gallo, C., and Perrone, F., “Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial”, J Clin Oncol, vol. 29, pp. 3628-35, 2011.Google Scholar 

G. J. S. Rustin, Vergote, I. B., Eisenhauer, E., Pujade-Lauraine, E., Quinn, M., Thigpen, T., du Bois, A., Kristensen, G. B., Jakobsen, A., Sagae, S., Greven, K., Parmar, M. K. B., Friedlander, M. Leonard, Cervantes, A., Vermorken, J. B., and Intergroup, G. Cancer, “Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG)”, Int J Gynecol Cancer, vol. 21, pp. 419-23, 2011.Google Scholar 

R. P. Symonds, Davidson, S. E., Chan, S., Reed, N. Simon, McMahon, T., Rai, D., Harden, S., Paul, J., Group, S. Gynaecolog, and Centre, B. West of Sc, “SCOTCERV: a phase II trial of docetaxel and gemcitabine as second line chemotherapy in cervical cancer”, Gynecol Oncol, vol. 123, pp. 105-9, 2011.Google Scholar 

T. Toita, Kato, S., Ishikura, S., Tsujino, K., Kodaira, T., Uno, T., Hatano, K., Sakurai, H., Niibe, Y., Kazumoto, T., Nishimura, T., Kitagawa, R., Fukutani, M., Oguchi, M., Umayahara, K., Hirashima, Y., Aoki, Y., Takizawa, K., and Group, D. Committee, “Radiotherapy quality assurance of the Japanese Gynecologic Oncology Group study (JGOG1066): a cooperative phase II study of concurrent chemoradiotherapy for uterine cervical cancer”, Int J Clin Oncol, vol. 16, pp. 379-86, 2011.Google Scholar 

J. - E. Kurtz, Kaminsky, M. C., Floquet, A., Veillard, A. S., Kimmig, R., Dorum, A., Elit, L., Buck, M., Petru, E., Reed, N. Simon, Scambia, G., Varsellona, N., Brown, C., and Pujade-Lauraine, E., “Ovarian cancer in elderly patients: carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in late relapse: a Gynecologic Cancer Intergroup (GCIG) CALYPSO sub-study.”, Ann Oncol, vol. 22, no. 11, p. 2423, 2011.PubMed 

F. Joly, Ray-Coquard, I., Fabbro, M., Donoghoe, M., Boman, K., Sugimoto, A., Vaughan, M., Reinthaller, A., Vergote, I. B., Ferrandina, G., Dell'Anna, T., Huober, J., and Pujade-Lauraine, E., “Decreased hypersensitivity reactions with carboplatin-pegylated liposomal doxorubicin compared to carboplatin-paclitaxel combination: analysis from the GCIG CALYPSO relapsing ovarian cancer trial.”, Gynecol Oncol, vol. 122, no. 2, p. 232, 2011.PubMed 

P. Harter, Sehouli, J., Reuss, A., Hasenburg, A., Scambia, G., Cibula, D., Mahner, S., Vergote, I. B., Reinthaller, A., Burges, A., Hanker, L., Pölcher, M., Kurzeder, C., Canzler, U., Petry, K. Ulrich, Obermair, A., Petru, E., Schmalfeldt, B., Lorusso, D., and du Bois, A., “Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO.”, Int J Gynecol Cancer, vol. 21, no. 2, p. 295, 2011.PubMed 

T. J. Perren, Swart, A. Marie, Pfisterer, J., Ledermann, J. A., Pujade-Lauraine, E., Kristensen, G. B., Carey, M. S., Beale, P., Cervantes, A., Kurzeder, C., du Bois, A., Sehouli, J., Kimmig, R., Stähle, A., Collinson, F., Essapen, S., Gourley, C., Lortholary, A., Selle, F., Mirza, M. R., Leminen, A., Plante, M., Stark, D., Qian, W., Parmar, M. K. B., and Oza, A. M., “A phase 3 trial of bevacizumab in ovarian cancer.”, N Engl J Med, vol. 365, no. 26, p. 2496, 2011.PubMed 

C. Khoon Lee, Simes, R. J., Brown, C., Lord, S., Wagner, U., Plante, M., Vergote, I. B., Pisano, C., Parma, G., Burges, A., Bourgeois, H., Högberg, T., Bentley, J., Angleitner-Boubenizek, L., Ferrero, A., Richter, B., Hirte, H., Gebski, V., Pfisterer, J., Pujade-Lauraine, E., and Friedlander, M. Leonard, “Prognostic nomogram to predict progression-free survival in patients with platinum-sensitive recurrent ovarian cancer.”, Br J Cancer, vol. 105, no. 8, pp. 1144-50, 2011.PubMed DOI 

M. Leonard Friedlander, Trimble, E. L., Tinker, A., Alberts, D. S., Åvall-Lundqvist, E., Brady, M. F., Harter, P., Pignata, S., Pujade-Lauraine, E., Sehouli, J., Vergote, I. B., Beale, P., Bekkers, R., Calvert, P., Copeland, L., Glasspool, R. M., Gonzalez-Martin, A., Katsaros, D., Kim, J. Won, Miller, B., Provencher, D. M., Rubinstein, L., Atri, M., Zeimet, A. G., Bacon, M., Kitchener, H. C., and Stuart, G. C. E., “Clinical trials in recurrent ovarian cancer.”, Int J Gynecol Cancer, vol. 21, no. 4, pp. 771-5, 2011.PubMed 

J. A. Ledermann, Marth, C., Carey, M. S., Birrer, M. J., Bowtell, D. D. L., Kaye, S. B., McNeish, I., Oza, A. M., Scambia, G., Rustin, G. J. S., Stehman, F. B., Gershenson, D., Thomas, G., Berns, E. M. J. J., Casado, A., Ottevanger, N., Hilpert, F., Kim, B. - G., Okamoto, A., Bacon, M., Kitchener, H. C., and Stuart, G. C. E., “Role of molecular agents and targeted therapy in clinical trials for women with ovarian cancer.”, Int J Gynecol Cancer, vol. 21, no. 4, pp. 763-70, 2011.PubMed 

G. C. E. Stuart, Kitchener, H. C., Bacon, M., du Bois, A., Friedlander, M. Leonard, Ledermann, J. A., Marth, C., Thigpen, T., and Trimble, E. L., “2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference.”, Int J Gynecol Cancer, vol. 21, no. 4, pp. 750-5, 2011.PubMed 

F. A. Raja, Griffin, C. L., Qian, W., Hirte, H., Parmar, M. K. B., Swart, A. Marie, and Ledermann, J. A., “Initial toxicity assessment of ICON6: a randomised trial of cediranib plus chemotherapy in platinum-sensitive relapsed ovarian cancer.”, Br J Cancer, vol. 105, no. 7, pp. 884-9, 2011.PubMed 

T. Thigpen, du Bois, A., McAlpine, J., DiSaia, P., Fujiwara, K., Hoskins, W. J., Kristensen, G. B., Mannel, R., Markman, M., Pfisterer, J., Quinn, M., Reed, N. Simon, Swart, A. Marie, Berek, J. S., Colombo, N., Freyer, G., Gallardo, D., Plante, M., Poveda, A. M., Rubinstein, L., Bacon, M., Kitchener, H. C., and Stuart, G. C. E., “First-line therapy in ovarian cancer trials.”, Int J Gynecol Cancer, vol. 21, no. 4, pp. 756-62, 2011.PubMed 

M. Bacon, Kitchener, H. C., Stuart, G. C. E., and Vermorken, J. B., “The global impact of the Gynecologic Cancer InterGroup in enhancing clinical trials in ovarian cancer.”, Int J Gynecol Cancer, vol. 21, no. 4, pp. 746-9, 2011.PubMed 

H. Nomura, Aoki, D., Takahashi, F., Katsumata, N., Watanabe, Y., Konishi, I., Jobo, T., Hatae, M., Hiura, M., and Yaegashi, N., “Randomized phase II study comparing docetaxel plus cisplatin, docetaxel plus carboplatin, and paclitaxel plus carboplatin in patients with advanced or recurrent endometrial carcinoma: a Japanese Gynecologic Oncology Group study (JGOG2041).”, Ann Oncol, vol. 22, no. 3, pp. 636-42, 2011.PubMed 

S. Kumagai, Sugiyama, T., Shoji, T., Michimae, H., Katsumata, N., Aoki, D., Terauchi, F., Jobo, T., Ochiai, K., and Yasuda, M., “Does severe anemia caused by dose-dense paclitaxel-Carboplatin combination therapy have an effect on the survival of patients with epithelial ovarian cancer? Retrospective analysis of the Japanese gynecologic oncology group 3016 trial.”, Int J Gynecol Cancer, vol. 21, no. 9, pp. 1585-91, 2011.PubMed 

K. Lim, Small, W., Portelance, L., Creutzberg, C., Jürgenliemk-Schulz, I. M., Mundt, A. J., Mell, L. K., Mayr, N., Viswanathan, A., Jhingran, A., Erickson, B., Santos, J. De Los, Gaffney, D. K., Yashar, C., Beriwal, S., Wolfson, A., Taylor, A., Bosch, W., Naqa, I. El, and Fyles, A., “Consensus guidelines for delineation of clinical target volume for intensity-modulated pelvic radiotherapy for the definitive treatment of cervix cancer.”, Int J Radiat Oncol Biol Phys, vol. 79, no. 2, pp. 348-55, 2011.PubMed 

M. S. Anglesio, Carey, M. S., Köbel, M., Mackay, H., and Huntsman, D. G., “Clear cell carcinoma of the ovary: a report from the first Ovarian Clear Cell Symposium, June 24th, 2010.”, Gynecol Oncol, vol. 121, no. 2, pp. 407-15, 2011.PubMed 

, “a phase III trial of carboplatin and paclitaxel plus placebo versus carboplatin and paclitaxel plus concurrent bevacizumab followed by placebo, versus carboplatin and paclitaxel plus concurrent and extended bevacizumab, in women with newly diagnosied, pre”, N Engl J Med, vol. 365, p. 2483, 2011.Google Scholar 

M. S. Carey and Gotay, C., “Patient-reported outcomes: clinical trials in ovarian cancer.”, Int J Gynecol Cancer, vol. 21, no. 4, pp. 782-7, 2011.PubMed 

G. Freyer and Tinker, A. V., “Clinical trials and treatment of the elderly diagnosed with ovarian cancer.”, Int J Gynecol Cancer, vol. 21, no. 4, pp. 776-81, 2011.PubMed 

T. J. Herzog, Vermorken, J. B., Pujade-Lauraine, E., Provencher, D. M., Jagiello-Gruszfeld, A., Kong, B., Boman, K., Park, Y. Choi, Parekh, T., Lebedinsky, C., Gómez, J., and Monk, B. J., “Correlation between CA-125 serum level and response by RECIST in a phase III recurrent ovarian cancer study.”, Gynecol Oncol, vol. 122, no. 2, pp. 350-5, 2011.PubMed 

G. B. Kristensen, Perren, T. J., Qian, W., Pfisterer, J., Ledermann, J. A., Joly, F., Carey, M. S., Beale, P., Cervantes, A., and Oza, A. M., “Result of interim analysis of overall survival in the phase III randomized trial of bevacizumab in women with newly diagnosed ovarian cancer. ”, J Clin Oncol , vol. 29, no. suppl; abstr LBA5006, 2011.Google Scholar 

C. Kurzeder, L, Z., Eisenhauer, E., Vergote, I. B., du Bois, A., D, T., Y, W., JF, G., HW, H., B, R., LC, H., Bentley, J., Wagner, U., Plante, M., Kimmig, R., and Pfisterer, J., “The impact of dose intensity on the efficacy of gemcitabine plus carboplatin (GC) therapy for recurrent platinum-sensitive ovarian cancer (PSOC): A retrospective analysis of AGO-OVAR 2.5. ”, J Clin Oncol , vol. 29, no. suppl; abstr 5088, 2011.Google Scholar 

L. C, Simes, R. J., Gebski, V., Wollschlaeger, K., Plante, M., Vergote, I. B., Maenpaa, J. U., Ferrero, A., Pisano, C., Parma, G., Berton-Rigaud, D., der W, S., Bentley, J., Reinthaller, A., Schmalfeldt, B., Hirte, H., Pfisterer, J., Pujade-Lauraine, E., and Friedlander, M. Leonard, “Development and validation of a nomogram to predict survival in CALYPSO and AGO-2.5 patients with platinum sensitive recurrent ovarian cancer. ”, Int J Gynecol Cancer , vol. 21, no. 12 Suppl 3, 2011.Google Scholar

J. Alexandre, Ray-Coquard, I., Selle, F., Floquet, A., Cottu, P., Weber, B., Falandry, C., Lebrun, D., Pujade-Lauraine, E., and , “Mucinous advanced epithelial ovarian carcinoma: clinical presentation and sensitivity to platinum-paclitaxel-based chemotherapy, the GINECO experience”, Ann Oncol, vol. 21, pp. 2377-81, 2010.Google Scholar 

A. Fagotti, Fanfani, F., Vizzielli, G., Gallotta, V., Ercoli, A., Paglia, A., Costantini, B., Vigliotta, M., Scambia, G., and Ferrandina, G., “Should laparoscopy be included in the work-up of advanced ovarian cancer patients attempting interval debulking surgery?”, Gynecol Oncol, vol. 116, pp. 72-7, 2010.Google Scholar 

M. C. Gainford, Tinker, A., Carter, J., Petru, E., Nicklin, J., Quinn, M., Hammond, I., Elit, L., Lenhard, M., and Friedlander, M. Leonard, “Malignant transformation within ovarian dermoid cysts: an audit of treatment received and patient outcomes. an Australia New Zealand gynaecological oncology group (ANZGOG) and gynaecologic cancer intergroup (GCIG) study”, Int J Gynecol Cancer, vol. 20, pp. 75-81, 2010.Google Scholar 

T. Högberg, Signorelli, M., de Oliveira, C. F., Fossati, R., Lissoni, A., Sorbe, B., Andersson, H., Grenman, S., Lundgren, C., Rosenberg, P., Boman, K., Tholander, B., Scambia, G., Reed, N. Simon, Cormio, G., Tognon, G., Clarke, J., Sawicki, T., Zola, P., and Kristensen, G. B., “Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer–results from two randomised studies”, Eur J Cancer, vol. 46, pp. 2422-31, 2010.Google Scholar 

H. C. Kitchener, Hoskins, W. J., Small, W., Thomas, G. M., Trimble, E. L., and Group, C. Cancer Con, “The development of priority cervical cancer trials: a Gynecologic Cancer InterGroup report”, Int J Gynecol Cancer, vol. 20, pp. 1092-100, 2010.Google Scholar 

H. Mackay, Brady, M. F., Oza, A. M., Reuss, A., Pujade-Lauraine, E., Swart, A. Marie, Siddiqui, N. Ahmad, Colombo, N., Bookman, M. A., Pfisterer, J., du Bois, A., and InterGroup, G. Cancer, “Prognostic relevance of uncommon ovarian histology in women with stage III/IV epithelial ovarian cancer”, Int J Gynecol Cancer, vol. 20, pp. 945-52, 2010.Google Scholar 

G. Mangili, Scarfone, G., Gadducci, A., Sigismondi, C., Ferrandina, G., Scibilia, G., Vigano, R., Tateo, S., Villa, A., and Lorusso, D., “Is adjuvant chemotherapy indicated in stage I pure immature ovarian teratoma (IT)? A multicentre Italian trial in ovarian cancer (MITO-9)”, Gynecol Oncol, vol. 119, pp. 48-52, 2010.Google Scholar 

M. Quinn, “Progress in ovarian cancer trials: the GCIG consensus model–is bigger, better?”, Gynecol Oncol, vol. 119, pp. 5-6, 2010.Google Scholar 

I. Ray-Coquard, Weber, B., Lotz, J. P., Tournigand, C., Provencal, J., Mayeur, D., Treilleux, I., Paraiso, D., Duvillard, P., Pujade-Lauraine, E., and Group, G. I. N. E. C. O., “Management of rare ovarian cancers: the experience of the French website ""Observatory for rare malignant tumours of the ovaries"" by the GINECO group: interim analysis of the first 100 patients”, Gynecol Oncol, vol. 119, pp. 53-9, 2010.Google Scholar 

M. P. Smerdel, Steffensen, K. D., Waldstrom, M., Brandslund, I., and Jakobsen, A., “The predictive value of serum VEGF in multiresistant ovarian cancer patients treated with bevacizumab”, Gynecol Oncol, vol. 118, pp. 167-71, 2010.Google Scholar 

S. Takakura, Takano, M., Takahashi, F., Saito, T., Aoki, D., Inaba, N., Noda, K., Sugiyama, T., Ochiai, K., and Group, J. Gynecologi, “Randomized phase II trial of paclitaxel plus carboplatin therapy versus irinotecan plus cisplatin therapy as first-line chemotherapy for clear cell adenocarcinoma of the ovary: a JGOG study”, Int J Gynecol Cancer, vol. 20, pp. 240-7, 2010.Google Scholar 

S. A. Welch, Hirte, H., Elit, L., Schilder, R. J., Wang, L., Macalpine, K., Wright, J. J., and Oza, A. M., “Sorafenib in combination with gemcitabine in recurrent epithelial ovarian cancer: a study of the Princess Margaret Hospital Phase II Consortium”, Int J Gynecol Cancer, vol. 20, pp. 787-93, 2010.Google Scholar 

I. B. Vergote, Tropé, C. G., Amant, F., Kristensen, G. B., Ehlen, T., Johnson, N., Verheijen, R. H. M., van der Burg, M. E. L., Lacave, A. J., Panici, P. Benedetti, Kenter, G. G., Casado, A., Mendiola, C., Coens, C., Verleye, L., Stuart, G. C. E., Pecorelli, S., and Reed, N. Simon, “Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer.”, N Engl J Med, vol. 363, no. 10, pp. 943-53, 2010.PubMed 

B. Trimbos, Timmers, P., Pecorelli, S., Coens, C., Ven, K., van der Burg, M. E. L., and Casado, A., “Surgical staging and treatment of early ovarian cancer: long-term analysis from a randomized trial.”, J Natl Cancer Inst, vol. 102, no. 13, pp. 982-7, 2010.PubMed 

E. Pujade-Lauraine, Wagner, U., Åvall-Lundqvist, E., Gebski, V., Heywood, M., Vasey, P. A., Volgger, B., Vergote, I. B., Pignata, S., Ferrero, A., Sehouli, J., Lortholary, A., Kristensen, G. B., Jackisch, C., Joly, F., Brown, C., Le Fur, N., and du Bois, A., “Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse.”, J Clin Oncol, vol. 28, no. 20, pp. 3323-9, 2010.PubMed 

C. M Gainford, Tinker, A., Carter, J., Petru, E., Nicklin, J., Quinn, M., Hammond, I., Elit, L., Lenhard, M., and Friedlander, M. Leonard, “Malignant transformation within ovarian dermoid cysts: an audit of treatment received and patient outcomes. an Australia New Zealand gynaecological oncology group (ANZGOG) and gynaecologic cancer intergroup (GCIG) study.”, Int J Gynecol Cancer, vol. 20, no. 1, pp. 75-81, 2010.PubMed 

S. Pecorelli, Ray-Coquard, I., Tredan, O., Colombo, N., Parma, G., Tisi, G., Katsaros, D., Lhommé, C., Lissoni, A., Vermorken, J. B., du Bois, A., Poveda, A. M., Frigerio, L., Barbieri, P., Carminati, P., Brienza, S., and Guastalla, J. P., “Phase II of oral gimatecan in patients with recurrent epithelial ovarian, fallopian tube or peritoneal cancer, previously treated with platinum and taxanes.”, Ann Oncol, vol. 21, no. 4, pp. 759-65, 2010.PubMed 

T. J. Perren, Swart, A. Marie, Pfisterer, J., Ledermann, J. A., Lortholary, A., Kristensen, G. B., Carey, M. S., Beale, P., Cervantes, A., and Oza, A. M., “. ICON7: A phase III randomised Gynaecologic Cancer InterGroup trial of concurrent bevacizumab and chemotherapy followed by maintenance bevacizumab, versus chemotherapy alone in women with newly diagnosed epithelial ovarian, primary peritoneal or fallopia”, Ann Oncol , vol. 21, no. Suppl 8, abstr LBA4, 2010.Google Scholar 

E. L. Trimble, Birrer, M. J., Hoskins, W. J., Marth, C., Petryshyn, R., Quinn, M., Thomas, G. M., Kitchener, H. C., Aghajanian, C., Alberts, D. S., Armstrong, D., Brown, J., Coleman, R. L., Colombo, N., Eisenhauer, E., Friedlander, M. Leonard, Fujiwara, K., Hunsberger, S., Kaye, S. B., Ledermann, J. A., Lee, S., Look, K., Mannel, R., McNeish, I. A., Minasian, L. M., Oza, A. M., Paul, J., Poveda, A. M., Pujade-Lauraine, E., Schoenfeldt, M., Swart, A. Marie, von Gruenigen, V., and Wenzel, L. B., “Current academic clinical trials in ovarian cancer: Gynecologic Cancer Intergroup and US National Cancer Institute Clinical Trials Planning Meeting, May 2009.”, Int J Gynecol Cancer, vol. 20, no. 7, pp. 1290-8, 2010.PubMed

D. K. Gaffney, du Bois, A., Narayan, K., Reed, N. Simon, Toita, T., Pignata, S., Blake, P., Portelance, L., Sadoyze, A., Potter, R., Colombo, A., Randall, M., Mirza, M. R., and Trimble, E. L., “Patterns of care for radiotherapy in vulvar cancer: a Gynecologic Cancer Intergroup study”, Int J Gynecol Cancer, vol. 19, pp. 163-7, 2009.Google Scholar 

N. Katsumata, Yasuda, M., Takahashi, F., Isonishi, S., Jobo, T., Aoki, D., Tsuda, H., Sugiyama, T., Kodama, S., Kimura, E., Ochiai, K., Noda, K., and Group, J. Gynecologi, “Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial”, Lancet, vol. 374, pp. 1331-8, 2009.Google Scholar 

E. Petru, Luck, H. J., Stuart, G. C. E., Gaffney, D. K., Millan, D., Vergote, I. B., and InterGroup, G. Cancer, “Gynecologic Cancer Intergroup (GCIG) proposals for changes of the current FIGO staging system”, Eur J Obstet Gynecol Reprod Biol, vol. 143, pp. 69-74, 2009.Google Scholar 

S. Pignata, Scambia, G., Savarese, A., Breda, E., Sorio, R., Pisano, C., Lorusso, D., Cognetti, F., A. Lombardi, V., Gebbia, V., Scollo, P., Morabito, A., Signoriello, G., and Perrone, F., “Carboplatin and pegylated liposomal doxorubicin for advanced ovarian cancer: preliminary activity results of the MITO-2 phase III trial”, Oncology, vol. 76, pp. 49-54, 2009.Google Scholar 

C. Pisano, Morabito, A., Sorio, R., Breda, E., Lauria, R., Gebbia, V., Scaltriti, L., Scalone, S., Zagonel, V., Greggi, S., Beneduce, G., Losito, S., Gallo, C., Di Maio, M., Forestieri, V., and Pignata, S., “A phase II study of capecitabine in the treatment of ovarian cancer resistant or refractory to platinum therapy: a multicentre Italian trial in ovarian cancer (MITO-6) trial”, Cancer Chemother Pharmacol, vol. 64, pp. 1021-7, 2009.Google Scholar 

I. Ray-Coquard, Weber, B., Cretin, J., Haddad-Guichard, Z., Levy, E., Hardy-Bessard, A. C., Gouttebel, M. C., Geay, J. - F., Aleba, A., Orfeuvre, H., Agostini, C., Provencal, J., Ferrero, J. M., Fric, D., Dohollou, N., Paraiso, D., Salvat, J., Pujade-Lauraine, E., and Group, G. I. N. E. C. O., “Gemcitabine-oxaliplatin combination for ovarian cancer resistant to taxane-platinum treatment: a phase II study from the GINECO group”, Br J Cancer, vol. 100, pp. 601-7, 2009.Google Scholar 

M. Signorelli, Lissoni, A., Cormio, G., Katsaros, D., Pellegrino, A., Selvaggi, L., Ghezzi, F., Scambia, G., Zola, P., Grassi, R., Milani, R., Giannice, R., Caspani, G., Mangioni, C., Floriani, I., Rulli, E., and Fossati, R., “Modified radical hysterectomy versus extrafascial hysterectomy in the treatment of stage I endometrial cancer: results from the ILIADE randomized study”, Ann Surg Oncol, vol. 16, pp. 3431-41, 2009.Google Scholar 

"W. Small, du Bois, A., Bhatnagar, S., Reed, N. Simon, Pignata, S., Potter, R., Randall, M., Mirza, M., Trimble, E. L., Gaffney, D. K., and InterGroup, G. Cancer, “Practice patterns of radiotherapy in endometrial cancer among member groups of the Gynecologic Cancer Intergroup”, Int J Gynecol Cancer, vol. 19, pp. 395-9, 2009.Google Scholar 

T. Sugiyama, Kumagai, S., and Hatayama, S., “[Treatments of epithelial ovarian cancer by histologic subtype]”, Gan To Kagaku Ryoho, vol. 36, pp. 187-92, 2009.Google Scholar 

I. B. Vergote, Calvert, A. H., Kania, M., Kaiser, C., Zimmermann, A. Hayden, and Sehouli, J., “A randomised, double-blind, phase II study of two doses of pemetrexed in the treatment of platinum-resistant, epithelial ovarian or primary peritoneal cancer”, Eur J Cancer, vol. 45, pp. 1415-23, 2009.Google Scholar 

Y. Watanabe, Kitagawa, R., Aoki, D., Takeuchi, S., Sagae, S., Sakuragi, N., Yaegashi, N., and Group, D. Committee, “Practice pattern for postoperative management of endometrial cancer in Japan: a survey of the Japanese Gynecologic Oncology Group”, Gynecol Oncol, vol. 115, pp. 456-9, 2009.Google Scholar 

H. C. Kitchener, Swart, A. Marie, Qian, Q., Amos, C., and Parmar, M. K. B., “Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study.”, Lancet, vol. 373, no. 9658, pp. 125-36, 2009.PubMed 

M. A. Bookman, Brady, M. F., McGuire, W. P., Harper, P. G., Alberts, D. S., Friedlander, M. Leonard, Colombo, N., Fowler, J. M., Argenta, P. A., De Geest, K., Mutch, D. G., Burger, R. A., Swart, A. Marie, Trimble, E. L., Accario-Winslow, C., and Roth, L. M., “Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup.”, J Clin Oncol, vol. 27, no. 9, pp. 1419-25, 2009.PubMed 

P. Blake, Swart, A. Marie, Orton, J., Kitchener, H. C., Whelan, T., Lukka, H., Eisenhauer, E., Bacon, M., Tu, D., Parmar, M. K. B., Amos, C., Murray, C., and Qian, W., “Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review, and meta-analysis.”, Lancet, vol. 373, no. 9658, pp. 137-46, 2009.PubMed 

H. C. Kitchener and Trimble, E. L., “Endometrial cancer state of the science meeting.”, Int J Gynecol Cancer, vol. 19, no. 1, pp. 134-40, 2009.PubMed 

A. M. Poveda and Vermorken, J. B., “The International Symposium on Advanced Ovarian Cancer. February 27, 2009, Spain.”, Int J Gynecol Cancer, vol. 19 Suppl 2, p. S1, 2009.PubMed 

E. Pujade-Lauraine, Mahner, S., Kaern, J., Gebski, V., Heywood, M., Vasey, P. A., Reinthaller, A., Vergote, I. B., Pignata, S., and Ferrero, A., “A randomized, phase III study of carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in relapsed platinum-sensitive ovarian cancer: CALYPSO study of the Gynecologic Cancer Intergroup.”, J Clin Oncol , vol. 27, no. 18, 2009.Google Scholar

S. V. Barrett, Paul, J., Hay, A., Vasey, P. A., Kaye, S. B., Glasspool, R. M., and Group, S. Gynaecolog, “Does body mass index affect progression-free or overall survival in patients with ovarian cancer? Results from SCOTROC I trial”, Ann Oncol, vol. 19, pp. 898-902, 2008.Google Scholar 

G. Ferrandina, Ludovisi, M., Corrado, G., Carone, V., Petrillo, M., and Scambia, G., “Prognostic role of Ca125 response criteria and RECIST criteria: analysis of results from the MITO-3 phase III trial of gemcitabine versus pegylated liposomal doxorubicin in recurrent ovarian cancer”, Gynecol Oncol, vol. 109, pp. 187-93, 2008.Google Scholar 

S. Pignata, Breda, E., Scambia, G., Pisano, C., Zagonel, V., Lorusso, D., Greggi, S., De Vivo, R., Ferrandina, G., Gallo, C., and Perrone, F., “A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer. A Multicentre Italian Trial in Ovarian cancer (MITO-5) study”, Crit Rev Oncol Hematol, vol. 66, pp. 229-36, 2008.Google Scholar 

A. M. Poveda, “Ten years of ""Optimal Therapy in Advanced Ovarian Cancer. Update"" meeting”, Int J Gynecol Cancer, vol. 18 Suppl 1, pp. 67-70, 2008.Google Scholar 

G. C. E. Stuart, “Future opportunities of the Gynecological Cancer Intergroup”, Int J Gynecol Cancer, vol. 18 Suppl 1, pp. 71-3, 2008.Google Scholar 

N. Susumu, Sagae, S., Udagawa, Y., Niwa, K., Kuramoto, H., Satoh, S., Kudo, R., and Group, J. Gynecologi, “Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: a Japanese Gynecologic Oncology Group study”, Gynecol Oncol, vol. 108, pp. 226-33, 2008.Google Scholar 

P. A. Vasey, Gore, M. E., Wilson, R. H., Rustin, G. J. S., Gabra, H., Guastalla, J. P., Lauraine, E. P., Paul, J., Carty, K., Kaye, S. B., and Group, S. Gynaecolog, “A phase Ib trial of docetaxel, carboplatin and erlotinib in ovarian, fallopian tube and primary peritoneal cancers”, Br J Cancer, vol. 98, pp. 1774-80, 2008.Google Scholar 

E. Åvall-Lundqvist, Wimberger, P., Gladieff, L., Gebski, V., Huober, J., Floquet, A., Fitzharris, B., Zeimet, A. G., Heywood, M., and Schmalfeldt, B., “Pegylated liposomal doxorubicin-carboplatin vs paclitaxel-carboplatin in relapsing sensitive ovarian cancer: a 500-patient interim safety analysis of the CALYPSO GCIG intergroup phase III study. ”, Proc.Am.Soc.Clin.Oncol. , vol. 26, no. 15S Part I, 2008.Google Scholar 

M. S. Carey, Bacon, M., Tu, D., Butler, L., Bezjak, A., and Stuart, G. C. E., “The prognostic effects of performance status and quality of life scores on progression-free survival and overall survival in advanced ovarian cancer.”, Gynecol Oncol, vol. 108, no. 1, pp. 100-5, 2008.PubMed 

E. Eisenhauer, “Addressing unanswered questions in ovarian cancer trial methodology: follow-up of the 2004 Baden-Baden Gynecologic Cancer Intergroup meeting.”, Int J Gynecol Cancer, vol. 18 Suppl 1, pp. 74-5, 2008.PubMed 

P. Hoskins, Vergote, I. B., Stuart, G. C. E., Cervantes, A., Tu, D., Carey, M. S., Provencher, D. M., Katsaros, D., P, G., and Eisenhauer, E., “A phase III trial of cisplatin plus topotecan followed by paclitaxel plus carboplatin versus standard carboplatin plus paclitaxel as first-line chemotherapy in women with newly diagnosed advanced epithelial ovarian cancer (OV.16). A GCIG Study.”, Proc.Am.Soc.Clin.Oncol. , vol. 26, no. 15S Part I, 2008.Google Scholar 

R. Osborne, Filiaci, V. L., J, S., Mannel, R., Lage, J., A, A. - S., J, K., Provencher, D. M., Schilder, R. J., and Miller, D. S., “A randomized phase III trial comparing weekly parenteral methotrexate and ""pulsed"" dactinomycin as primary management for low-risk gestational trophoblastic neoplasia. ”, Society Gynecologic Oncologists, 2008.Google Scholar 

N. Simon Reed, Mangioni, C., Malmström, H., Scarfone, G., Poveda, A. M., Pecorelli, S., Tateo, S., Franchi, M., Jobsen, J. J., Coens, C., Teodorovic, I., Vergote, I. B., and Vermorken, J. B., “Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874).”, Eur J Cancer, vol. 44, no. 6, pp. 808-18, 2008.PubMed 

W. Small, Mell, L. K., Anderson, P., Creutzberg, C., Santos, J. De Los, Gaffney, D. K., Jhingran, A., Portelance, L., Schefter, T., Iyer, R., Varia, M., Winter, K., and Mundt, A. J., “Consensus guidelines for delineation of clinical target volume for intensity-modulated pelvic radiotherapy in postoperative treatment of endometrial and cervical cancer.”, Int J Radiat Oncol Biol Phys, vol. 71, no. 2, pp. 428-34, 2008.PubMed 

G. C. E. Stuart, “Future opportunities of the Gynecological Cancer Intergroup.”, Int J Gynecol Cancer, vol. 18 Suppl 1, pp. 71-3, 2008.PubMed 

L. Verleye, PB, O., Coens, C., Amant, F., Kristensen, G. B., Tropé, C. G., Johnson, N., HC, vanDoorn, Reed, N. Simon, Verheijen, R. H. M., Hoskins, P., Trimbos, B., B, M., Mendiola, C., J, vander Velden, Eisenhauer, E., and Vergote, I. B., “Quality of surgery in advanced ovarian cancer: Audit of original surgery reports of 442 patients from the neoadjuvant trial. ”, Int Gyn Cancer Soc, 2008.Google Scholar 

L. Verleye, Coens, C., Amant, F., van der Burg, M. E. L., Johnson, N., Verheijen, R. H. M., Coronado, P., Reed, N. Simon, RJ, P., and Vergote, I. B., “Predictive value of C-ERB2 for response to first-line chemotherapy in 206 advanced-stage ovarian cancer patients. ”, Int Gyn Cancer Soc, 2008.Google Scholar 

T. J. Herzog, Powell, M. A., Rader, J. S., Gibb, R. K., Lippmann, L., Coleman, R. L., and Mutch, D. G., “Phase II evaluation of topotecan and navelbine in patients with recurrent ovarian, fallopian tube or primary peritoneal cancer.”, Gynecol Oncol, vol. 111, no. 3, pp. 467-73, 2008.PubMed

I. Cadron, Leunen, K., Amant, F., Van Gorp, T., Neven, P., and Vergote, I. B., “The ""Leuven"" dose-dense paclitaxel/carboplatin regimen in patients with recurrent ovarian cancer”, Gynecol Oncol, vol. 106, pp. 354-61, 2007.Google Scholar 

J. M. Ferrero, Weber, B., Geay, J. - F., Lepille, D., Orfeuvre, H., Combe, M., Mayer, F., Leduc, B., Bourgeois, H., Paraiso, D., and Pujade-Lauraine, E., “Second-line chemotherapy with pegylated liposomal doxorubicin and carboplatin is highly effective in patients with advanced ovarian cancer in late relapse: a GINECO phase II trial”, Ann Oncol, vol. 18, pp. 263-8, 2007.Google Scholar 

M. Leonard Friedlander, Buck, M., Wyld, D., Findlay, M., Fitzharris, B., De Souza, P., Davies, T., Kalimi, G., Allan, S., Perez, D., and Harnett, P., “Phase II study of carboplatin followed by sequential gemcitabine and paclitaxel as first-line treatment for advanced ovarian cancer”, Int J Gynecol Cancer, vol. 17, pp. 350-8, 2007.Google Scholar 

D. K. Gaffney, du Bois, A., Narayan, K., Reed, N. Simon, Toita, T., Pignata, S., Blake, P., Portelance, L., Sadoyze, A., Potter, R., Colombo, A., Randall, M., Mirza, M. R., and Trimble, E. L., “Practice patterns of radiotherapy in cervical cancer among member groups of the Gynecologic Cancer Intergroup (GCIG)”, Int J Radiat Oncol Biol Phys, vol. 68, pp. 485-90, 2007.Google Scholar 

S. Kommoss, du Bois, A., Ridder, R., Trunk, M. J., Schmidt, D., Pfisterer, J., Kommoss, F., and -OVAR, A. G. O., “Independent prognostic significance of cell cycle regulator proteins p16(INK4a) and pRb in advanced-stage ovarian carcinoma including optimally debulked patients: a translational research subprotocol of a randomised study of the Arbeitsgemeinschaft Gynaek”, Br J Cancer, vol. 96, pp. 306-13, 2007.Google Scholar 

V. Möbus, Wandt, H., Frickhofen, N., Bengala, C., Champion, K., Kimmig, R., Ostermann, H., Hinke, A., Ledermann, J. A., -OVAR/AIO, A. G. O., and , “Phase III trial of high-dose sequential chemotherapy with peripheral blood stem cell support compared with standard dose chemotherapy for first-line treatment of advanced ovarian cancer: intergroup trial of the AGO-Ovar/AIO and EBMT”, J Clin Oncol, vol. 25, pp. 4187-93, 2007.Google Scholar 

I. Ray-Coquard, Paraiso, D., Guastalla, J. P., Leduc, B., Guichard, F., Martin, C., Chauvenet, L., Haddad-Guichard, Z., Lepille, D., Orfeuvre, H., Gautier, H., Castera, D., and Pujade-Lauraine, E., “Intensified dose of cyclophosphamide with G-CSF support versus standard dose combined with platinum in first-line treatment of advanced ovarian cancer a randomised study from the GINECO group”, Br J Cancer, vol. 97, pp. 1200-5, 2007.Google Scholar 

O. Tredan, Geay, J. - F., Touzet, S., Delva, R., Weber, B., Cretin, J., Provencal, J., Martin, J., Stefani, L., Pujade-Lauraine, E., Freyer, G., and Ovariens, Gd'Investig, “Carboplatin/cyclophosphamide or carboplatin/paclitaxel in elderly patients with advanced ovarian cancer? Analysis of two consecutive trials from the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens”, Ann Oncol, vol. 18, pp. 256-62, 2007.Google Scholar 

Y. Watanabe, Aoki, D., Kitagawa, R., Takeuchi, S., Sagae, S., Sakuragi, N., Yaegashi, N., and Group, D. Committee, “Status of surgical treatment procedures for endometrial cancer in Japan: results of a Japanese Gynecologic Oncology Group survey”, Gynecol Oncol, vol. 105, pp. 325-8, 2007.Google Scholar 

D. K. Gaffney, du Bois, A., Narayan, K., Reed, N. Simon, Toita, T., Pignata, S., Blake, P., Portelance, L., Sadoyze, A., Pötter, R., Colombo, A., Randall, M., Mirza, M. R., and Trimble, E. L., “Practice patterns of radiotherapy in cervical cancer among member groups of the Gynecologic Cancer Intergroup (GCIG).”, Int J Radiat Oncol Biol Phys, vol. 68, no. 2, pp. 485-90, 2007.PubMed

D. Armstrong, Bundy, B. N., Wenzel, L. B., Huang, H., Baergen, R., Lele, S., Copeland, L., Walker, J. L., Burger, R. A., and Group, G. Oncology, “Intraperitoneal cisplatin and paclitaxel in ovarian cancer”, N Engl J Med, vol. 354, pp. 34-43, 2006.Google Scholar 

R. R. Barakat, Bundy, B. N., Spirtos, N. M., Bell, J. G., Mannel, R., and Study, G. Oncology G., “Randomized double-blind trial of estrogen replacement therapy versus placebo in stage I or II endometrial cancer: a Gynecologic Oncology Group Study”, J Clin Oncol, vol. 24, pp. 587-92, 2006.Google Scholar 

J. G. Bell, Brady, M. F., Young, R. C., Lage, J., Walker, J. L., Look, K. Y., Rose, G. S., Spirtos, N. M., and Group, G. Oncology, “Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group study”, Gynecol Oncol, vol. 102, pp. 432-9, 2006.Google Scholar 

H. Bourgeois, Joly, F., Pujade-Lauraine, E., Curé, H., Guastalla, J. P., Ferru, A., Chabrun, V., Chieze, S., and Tourani, J. M., “Phase I study of pegylated liposomal doxorubicin in combination with ifosfamide in pretreated ovarian cancer patients”, Am J Clin Oncol, vol. 29, pp. 399-404, 2006.Google Scholar 

A. R. Clamp, Maenpaa, J. U., Cruickshank, D. J., Ledermann, J. A., Wilkinson, P. M., Welch, R., Chan, S., Vasey, P. A., Sorbe, B., Hindley, A., Jayson, G. C., and Group, S. Gynaecolog, “SCOTROC 2B: Feasibility of carboplatin followed by docetaxel or docetaxel-irinotecan as first-line therapy for ovarian cancer”, Br J Cancer, vol. 94, pp. 55-61, 2006.Google Scholar 

A. du Bois, Schmalfeldt, B., Meier, W., Sehouli, J., Pfisterer, J., OVAR, A. Gynaekolog, Cancer, A. G. O. Study Grou, and Onkologie, N. Gesellscha, “Ovarian cancer–can intraperitoneal therapy be regarded as new standard in Germany?”, Int J Gynecol Cancer, vol. 16, pp. 1756-60, 2006.Google Scholar 

K. Greven, Winter, K., Underhill, K., Fontenesci, J., Cooper, J., and Burke, T., “Final analysis of RTOG 9708: adjuvant postoperative irradiation combined with cisplatin/paclitaxel chemotherapy following surgery for patients with high-risk endometrial cancer”, Gynecol Oncol, vol. 103, pp. 155-9, 2006.Google Scholar 

B. Gronlund, Hogdall, E. V., Christensen, I. J., Johansen, J. S., Norgaard-Pedersen, B., Engelholm, S. A., and Hogdall, C., “Pre-treatment prediction of chemoresistance in second-line chemotherapy of ovarian carcinoma: value of serological tumor marker determination (tetranectin, YKL-40, CASA, CA 125)”, Int J Biol Markers, vol. 21, pp. 141-8, 2006.Google Scholar 

M. L. Harrison, Hoskins, P., du Bois, A., Quinn, M., Rustin, G. J. S., Ledermann, J. A., Baron-Hay, S., and Friedlander, M. Leonard, “Small cell of the ovary, hypercalcemic type – analysis of combined experience and recommendation for management. A GCIG study”, Gynecol Oncol, vol. 100, pp. 233-8, 2006.Google Scholar 

H. Hirte, Vergote, I. B., Jeffrey, J. R., Grimshaw, R. N., Coppieters, S., Schwartz, B., Tu, D., Sadura, A., Brundage, M., and Seymour, L., “A phase III randomized trial of BAY 12-9566 (tanomastat) as maintenance therapy in patients with advanced ovarian cancer responsive to primary surgery and paclitaxel/platinum containing chemotherapy: a National Cancer Institute of Canada Clinical Trials G”, Gynecol Oncol, vol. 102, pp. 300-8, 2006.Google Scholar 

A. Maggioni, P. Panici, B., Dell'Anna, T., Landoni, F., Lissoni, A., Pellegrino, A., Rossi, R. S., Chiari, S., Campagnutta, E., Greggi, S., Angioli, R., Manci, N., Calcagno, M., Scambia, G., Fossati, R., Floriani, I., Torri, V., Grassi, R., and Mangioni, C., “Randomised study of systematic lymphadenectomy in patients with epithelial ovarian cancer macroscopically confined to the pelvis”, Br J Cancer, vol. 95, pp. 699-704, 2006.Google Scholar 

C. Marth, Windbichler, G. H., Hausmaninger, H., Petru, E., Estermann, K., Pelzer, A., and Mueller-Holzner, E., “Interferon-gamma in combination with carboplatin and paclitaxel as a safe and effective first-line treatment option for advanced ovarian cancer: results of a phase I/II study”, Int J Gynecol Cancer, vol. 16, pp. 1522-8, 2006.Google Scholar 

D. G. Mitchell, Snyder, B., Coakley, F., Reinhold, C., Thomas, G., Amendola, M., Schwartz, L. H., Woodward, P., Pannu, H., and Hricak, H., “Early invasive cervical cancer: tumor delineation by magnetic resonance imaging, computed tomography, and clinical examination, verified by pathologic results, in the ACRIN 6651/GOG 183 Intergroup Study”, J Clin Oncol, vol. 24, pp. 5687-94, 2006.Google Scholar 

E. Petru, Angleitner-Boubenizek, L., Reinthaller, A., Deibl, M., Zeimet, A. G., Volgger, B., Stempfl, A., and Marth, C., “Combined PEG liposomal doxorubicin and gemcitabine are active and have acceptable toxicity in patients with platinum-refractory and -resistant ovarian cancer after previous platinum-taxane therapy: a phase II Austrian AGO study”, Gynecol Oncol, vol. 102, pp. 226-9, 2006.Google Scholar 

J. Pfisterer, Plante, M., Vergote, I. B., du Bois, A., Hirte, H., Lacave, A. J., Wagner, U., Stähle, A., Stuart, G. C. E., Kimmig, R., Olbricht, S., Le, T., Emerich, J., Kuhn, W., Bentley, J., Jackisch, C., Luck, H. J., Rochon, J., Zimmermann, A. Hayden, Eisenhauer, E., -OVAR, A. G. O., -CTG, N. C. I. C., and -GCG, E. O. R. T. C., “Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG”, J Clin Oncol, vol. 24, pp. 4699-707, 2006.Google Scholar 

J. Pfisterer, Weber, B., Reuss, A., Kimmig, R., du Bois, A., Wagner, U., Bourgeois, H., Meier, W., Costa, S., Blohmer, J. - U., Lortholary, A., Olbricht, S., Stähle, A., Jackisch, C., Hardy-Bessard, A. C., Möbus, V., Quaas, J., Richter, B., Schröder, W., Geay, J. - F., Luck, H. J., Kuhn, W., Meden, H., Nitz, U., Pujade-Lauraine, E., -OVAR, A. G. O., and , “Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO”, J Natl Cancer Inst, vol. 98, pp. 1036-45, 2006.Google Scholar 

S. Pignata, De Placido, S., Biamonte, R., Scambia, G., Di Vagno, G., Colucci, G., Febbraro, A., Marinaccio, M., Lombardi, A. V., Manzione, L., Carteni, G., Nardi, M., Danese, S., Valerio, M. R., De Matteis, A., Massidda, B., Gasparini, G., Di Maio, M., Pisano, C., and Perrone, F., “Residual neurotoxicity in ovarian cancer patients in clinical remission after first-line chemotherapy with carboplatin and paclitaxel: the Multicenter Italian Trial in Ovarian cancer (MITO-4) retrospective study”, BMC Cancer, vol. 6, p. 5, 2006.Google Scholar 

S. Pignata, Scambia, G., Savarese, A., Breda, E., Scollo, P., De Vivo, R., Rossi, E., Gebbia, V., Natale, D., Del Gaizo, F., Naglieri, E., Ferro, A., Musso, P., D'Arco, A. M., Sorio, R., Pisano, C., Di Maio, M., Signoriello, G., Annunziata, A., Perrone, F., and Investigators, M. I. T. O., “Safety of a 3-weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: preliminary results of the MITO-2 randomized trial”, BMC Cancer, vol. 6, p. 202, 2006.Google Scholar 

M. Randall, Filiaci, V. L., Muss, H., Spirtos, N. M., Mannel, R., Fowler, J. M., Thigpen, J. T., Benda, J. A., and Study, G. Oncology G., “Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study”, J Clin Oncol, vol. 24, pp. 36-44, 2006.Google Scholar 

N. Simon Reed, Poole, C. J., Coleman, R. L., Parkin, D., Graham, J. D., Kaye, S. B., Ostrowski, J., Duncan, I., Paul, J., Hay, A., and Group, S. Gynaecolog, “A randomised comparison of treosulfan and carboplatin in patients with ovarian cancer: A study by the Scottish Gynaecological Cancer Trials Group (SGCTG)”, Eur J Cancer, vol. 42, pp. 179-85, 2006.Google Scholar 

C. L. Trimble, Kauderer, J., Zaino, R., Silverberg, S., Lim, P. C., ,, Alberts, D. S., and Curtin, J., “Concurrent endometrial carcinoma in women with a biopsy diagnosis of atypical endometrial hyperplasia: a Gynecologic Oncology Group study”, Cancer, vol. 106, pp. 812-9, 2006.Google Scholar 

P. A. Vasey, Atkinson, R. J., Osborne, R., Parkin, D., Symonds, R., Paul, J., Lewsley, L. A., Coleman, R. L., Reed, N. Simon, Kaye, S. B., and Rustin, G. J. S., “SCOTROC 2A: Carboplatin followed by docetaxel or docetaxel-gemcitabine as first-line chemotherapy for ovarian cancer”, Br J Cancer, vol. 94, pp. 62-8, 2006.Google Scholar 

P. Wimberger, Lehmann, N., Kimmig, R., Burges, A., Meier, W., Hoppenau, B., du Bois, A., and -OVAR, A. G. O., “Impact of age on outcome in patients with advanced ovarian cancer treated within a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR)”, Gynecol Oncol, vol. 100, pp. 300-7, 2006.Google Scholar 

J. Pfisterer, Plante, M., Vergote, I. B., du Bois, A., Hirte, H., Lacave, A. J., Wagner, U., Stähle, A., Stuart, G. C. E., Kimmig, R., Olbricht, S., Le, T., Emerich, J., Kuhn, W., Bentley, J., Jackisch, C., Lück, H. - J., Rochon, J., Zimmermann, A. Hayden, and Eisenhauer, E., “Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG.”, J Clin Oncol, vol. 24, no. 29, pp. 4699-707, 2006.PubMed 

H. Hirte, Vergote, I. B., Jeffrey, J. R., Grimshaw, R. N., Coppieters, S., Schwartz, B., Tu, D., Sadura, A., Brundage, M., and Seymour, L., “A phase III randomized trial of BAY 12-9566 (tanomastat) as maintenance therapy in patients with advanced ovarian cancer responsive to primary surgery and paclitaxel/platinum containing chemotherapy: a NCIC Group Study.”, Gynecol Oncol, vol. 102, no. 2, pp. 300-8, 2006.PubMed 

A. du Bois, Weber, B., Rochon, J., Meier, W., Goupil, A., Olbricht, S., Barats, J. - C., Kuhn, W., Orfeuvre, H., Wagner, U., Richter, B., Lueck, H. - J., Pfisterer, J., Costa, S., Schröder, W., Kimmig, R., and Pujade-Lauraine, E., “Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial. ”, J Clin Oncol, vol. 24, no. 7, pp. 1127-35, 2006.PubMed 

A. R. Clamp, Maenpaa, J. U., Cruickshank, D. J., Ledermann, J. A., Wilkinson, P. M., Welch, R., Chan, S., Vasey, P. A., Sorbe, B., Hindley, A., and Jayson, G. C., “SCOTROC 2B: feasibility of carboplatin followed by docetaxel or docetaxel-irinotecan as first-line therapy for ovarian cancer.”, Br J Cancer, vol. 94, no. 1, pp. 55-61, 2006.PubMed 

M. L. Harrison, Hoskins, P., du Bois, A., Quinn, M., Rustin, G. J. S., Ledermann, J. A., Baron-Hay, S., and Friedlander, M. Leonard, “Small cell of the ovary, hypercalcemic type -- analysis of combined experience and recommendation for management. A GCIG study.”, Gynecol Oncol, vol. 100, no. 2, pp. 233-8, 2006.PubMed 

H. C. Kitchener, “Management of endometrial cancer.”, Eur J Surg Oncol, vol. 32, no. 8, pp. 838-43, 2006.PubMed 

J. Pfisterer, Weber, B., Reuss, A., Kimmig, R., du Bois, A., Wagner, U., Bourgeois, H., Meier, W., Costa, S., Blohmer, J. - U., Lortholary, A., Olbricht, S., Stähle, A., Jackisch, C., Hardy-Bessard, A. - C., Möbus, V., Quaas, J., Richter, B., Schröder, W., Geay, J. - F., Lück, H. - J., Kuhn, W., Meden, H., Nitz, U., and Pujade-Lauraine, E., “Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO.”, J Natl Cancer Inst, vol. 98, no. 15, pp. 1036-45, 2006.PubMed 

G. J. S. Rustin, Timmers, P., Nelstrop, A., Shreeves, G., Bentzen, S. M., Baron, B., Piccart, M. J., Bertelsen, K., Stuart, G. C. E., Cassidy, J., and Eisenhauer, E., “Comparison of CA-125 and standard definitions of progression of ovarian cancer in the intergroup trial of cisplatin and paclitaxel versus cisplatin and cyclophosphamide.”, J Clin Oncol, vol. 24, no. 1, pp. 45-51, 2006.PubMed 

T. GM, S, A., M, P., O, A., and JA, III, L., “A GOG phase III trial to evaluate maintaining hemoglobin = 120 G/L with erythropoietin during chemoradiation for cervical cancer. ”, Int J Gynecol Cancer , vol. 16, no. 3, p. 604, 2006.Google Scholar

A. Buda, Fossati, R., Colombo, N., Fei, F., Floriani, I., D. Alletti, G., Katsaros, D., Landoni, F., Lissoni, A., Malzoni, C., Schröder, W., Scollo, P., Torri, V., Zola, P., and Mangioni, C., “Randomized trial of neoadjuvant chemotherapy comparing paclitaxel, ifosfamide, and cisplatin with ifosfamide and cisplatin followed by radical surgery in patients with locally advanced squamous cell cervical carcinoma: the SNAP01 (Studio Neo-Adjuvante Por”, J Clin Oncol, vol. 23, pp. 4137-45, 2005.Google Scholar 

S. C. Crawford, Vasey, P. A., Paul, J., Hay, A., Davis, J. A., and Kaye, S. B., “Does aggressive surgery only benefit patients with less advanced ovarian cancer? Results from an international comparison within the SCOTROC-1 Trial”, J Clin Oncol, vol. 23, pp. 8802-11, 2005.Google Scholar 

A. du Bois, Belau, A., Wagner, U., Pfisterer, J., Schmalfeldt, B., Richter, B., Stähle, A., Jackisch, C., Lueck, H. J., Schröder, W., Burges, A., Olbricht, S., Elser, G., and Group, A. Gynaekolog, “A phase II study of paclitaxel, carboplatin, and gemcitabine in previously untreated patients with epithelial ovarian cancer FIGO stage IC-IV (AGO-OVAR protocol OVAR-8)”, Gynecol Oncol, vol. 96, pp. 444-51, 2005.Google Scholar 

G. Freyer, Geay, J. - F., Touzet, S., Provencal, J., Weber, B., Jacquin, J. P., Ganem, G., Tubiana-Mathieu, N., Gisserot, O., and Pujade-Lauraine, E., “Comprehensive geriatric assessment predicts tolerance to chemotherapy and survival in elderly patients with advanced ovarian carcinoma: a GINECO study”, Ann Oncol, vol. 16, pp. 1795-800, 2005.Google Scholar 

Bundy, B. N., Grendys, Jr., E. C., Benda, J. A., McMeekin, D. S., Sorosky, J., Miller, D. S., Eaton, L. A., Fiorica, J. V., and Study, G. Oncology G., “Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study”, J Clin Oncol, vol. 23, pp. 4626-33, 2005.Google Scholar 

P. B. Panici, Maggioni, A., Hacker, N., Landoni, F., Ackermann, S., Campagnutta, E., Tamussino, K., Winter, R., Pellegrino, A., Greggi, S., Angioli, R., Manci, N., Scambia, G., Dell'Anna, T., Fossati, R., Floriani, I., Rossi, R. S., Grassi, R., Favalli, G., Raspagliesi, F., Giannarelli, D., Martella, L., and Mangioni, C., “Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial”, J Natl Cancer Inst, vol. 97, pp. 560-6, 2005.Google Scholar 

J. Pfisterer, Harter, P., Canzler, U., Richter, B., Jackisch, C., Hahmann, M., Hasenburg, A., Burges, A., Loibl, S., Gropp, M., Huober, J., Fink, D., du Bois, A., Committee, A. G. O. Ovarian, and Group, A. G. O. Ovarian Ca, “The role of surgery in recurrent ovarian cancer”, Int J Gynecol Cancer, vol. 15 Suppl 3, pp. 195-8, 2005.Google Scholar 

M. Quinn, Pfisterer, J., Åvall-Lundqvist, E., Bookman, M. A., Bowtell, D. D. L., Casado, A., Cervantes, A., Grenman, S., Harper, P., Oza, A. M., Pecorelli, S., Pujade-Lauraine, E., Trimble, E. L., Vasey, P. A., Wagner, U., ,, -OVAR, A. G. O., ,, ,, ,, ,, /NCRI, M. R. C., -CTG, N. C. I. C., ,, ,, -US, N. C. I., and , “Integration of new or experimental treatment options and new approaches to clinical trials”, Ann Oncol, vol. 16 Suppl 8, pp. viii30-viii35, 2005.Google Scholar 

T. Thigpen, Stuart, G. C. E., du Bois, A., Friedlander, M. Leonard, Fujiwara, K., Guastalla, J. P., Kaye, S. B., Kitchener, H. C., Kristensen, G. B., Mannel, R., Meier, W., Miller, B., Poveda, A. M., Provencher, D. M., Stehman, F. B., Vergote, I. B., InterGroup, G. Cancer, ,, -CTG, N. C. I. C., -OVAR, A. G. O., ,, ,, ,, ,, /NCRI, M. R. C., ,, ,, ,, and , “Clinical trials in ovarian carcinoma: Requirements for standard approaches and regimens”, Ann Oncol, vol. 16 Suppl 8, pp. viii13-viii19, 2005.Google Scholar 

J. B. Vermorken, Åvall-Lundqvist, E., Pfisterer, J., Bacon, M., ,, -OVAR, A. G. O., ,, -GCC, E. O. R. T. C., ,, ,, ,, ,, ,, -CTG, N. C. I. C., -US, N. C. I., ,, ,, and , “The Gynecologic Cancer Intergroup (GCIG): History and current status”, Ann Oncol, vol. 16 Suppl 8, pp. viii39-viii42, 2005.Google Scholar 

J. B. Vermorken, Parmar, M. K. B., Brady, M. F., Eisenhauer, E., Högberg, T., Ozols, R. F., Rochon, J., Rustin, G. J. S., Sagae, S., Verheijen, R. H. M., InterGroup, G. Cancer, ,, /NCRI, M. R. C., ,, -CTG, N. C. I. C., ,, -OVAR, A. G. O., and , “Clinical trials in ovarian carcinoma: study methodology”, Ann Oncol, vol. 16 Suppl 8, pp. viii20-viii29, 2005.Google Scholar 

A. du Bois, Quinn, M., Thigpen, T., Vermorken, J. B., Åvall-Lundqvist, E., Bookman, M. A., Bowtell, D. D. L., Brady, M. F., Casado, A., Cervantes, A., Eisenhauer, E., Friedlander, M. Leonard, Fujiwara, K., Grenman, S., Guastalla, J. P., Harper, P., Högberg, T., Kaye, S. B., Kitchener, H. C., Kristensen, G. B., Mannel, R., Meier, W., Miller, B., Neijt, J. P., Oza, A. M., Ozols, R., Parmar, M. K. B., Pecorelli, S., Pfisterer, J., Poveda, A. M., Provencher, D. M., Pujade-Lauraine, E., Randall, M., Rochon, J., Rustin, G. J. S., Sagae, S., Stehman, F. B., Stuart, G. C. E., Trimble, E. L., Vasey, P. A., Vergote, I. B., Verheijen, R. H. M., and Wagner, U., “2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004).”, Ann Oncol, vol. 16 Suppl 8, pp. viii7-viii12, 2005.PubMed 

J. A. Green, F, D., Coens, C., S, L., Vergote, I. B., Eisenhauer, E., Bacon, M., W, C., van der Burg, M. E. L., and Oza, A. M., “Prognostic value of clinical and molecular markers in advanced ovarian cancer: importance of residual disease. Translational study using tumor specimens from EORTC 55931/NCIC OV10 phase III randomized clinical trial. ”, Proc Am Soc Clin Oncol , vol. 23, no. 16S Part 1, 2005.Google Scholar 

H. C. Kitchener, “Adjuvant chemotherapy improves survival after resection of stage 1 ovarian cancer.”, Cancer Treat Rev, vol. 31, no. 4, pp. 323-7, 2005.PubMed 

J. Pfisterer, Vergote, I. B., du Bois, A., and Eisenhauer, E., “Combination therapy with gemcitabine and carboplatin in recurrent ovarian cancer.”, Int J Gynecol Cancer, vol. 15 Suppl 1, pp. 36-41, 2005.PubMed 

M. Quinn, Pfisterer, J., Åvall-Lundqvist, E., Bookman, M. A., Bowtell, D. D. L., Casado, A., Cervantes, A., Grenman, S., Harper, P., Oza, A. M., Pecorelli, S., Pujade-Lauraine, E., Trimble, E. L., Vasey, P. A., and Wagner, U., “Integration of new or experimental treatment options and new approaches to clinical trials.”, Ann Oncol, vol. 16 Suppl 8, pp. viii30-viii35, 2005.PubMed 

M. Quinn, Åvall-Lundqvist, E., du Bois, A., Vermorken, J. B., Parmar, M. K. B., Pfisterer, J., Stuart, G. C. E., Thigpen, T., and Neijt, J., “History, scope and methodology of the 3rd International Consensus Workshop on Ovarian Cancer 2004.”, Ann Oncol, vol. 16 Suppl 8, pp. viii5-viii6, 2005.PubMed 

G. C. E. Stuart, Åvall-Lundqvist, E., du Bois, A., Bookman, M. A., Bowtell, D. D. L., Brady, M. F., Casado, A., Cervantes, A., Eisenhauer, E., Friedlander, M. Leonard, Fujiwara, K., Grenman, S., Guastalla, J. P., Harper, P., Högberg, T., Kaye, S. B., Kitchener, H. C., Kristensen, G. B., Mannel, R., Meier, W., Miller, B., Oza, A. M., Ozols, R., Parmar, M. K. B., Pfisterer, J., Poveda, A. M., Provencher, D. M., Pujade-Lauraine, E., Quinn, M., Randall, M., Rochon, J., Rustin, G. J. S., Sagae, S., Stehman, F. B., Trimble, E. L., Thigpen, T., Vasey, P. A., Vergote, I. B., Verheijen, R. H. M., Vermorken, J. B., and Wagner, U., “3rd International Ovarian Cancer Consensus Conference: outstanding issues for future consideration.”, Ann Oncol, vol. 16 Suppl 8, pp. viii36-viii38, 2005.PubMed 

T. Thigpen, Stuart, G. C. E., du Bois, A., Friedlander, M. Leonard, Fujiwara, K., Guastalla, J. P., Kaye, S. B., Kitchener, H. C., Kristensen, G. B., Mannel, R., Meier, W., Miller, B., Poveda, A. M., Provencher, D. M., Stehman, F. B., and Vergote, I. B., “Clinical trials in ovarian carcinoma: requirements for standard approaches and regimens.”, Ann Oncol, vol. 16 Suppl 8, pp. viii13-viii19, 2005.PubMed 

J. B. Vermorken, Parmar, M. K. B., Brady, M. F., Eisenhauer, E., Högberg, T., Ozols, R. F., Rochon, J., Rustin, G. J. S., Sagae, S., and Verheijen, R. H. M., “Clinical trials in ovarian carcinoma: study methodology.”, Ann Oncol, vol. 16 Suppl 8, pp. viii20-viii29, 2005.PubMed 

J. B. Vermorken, Åvall-Lundqvist, E., Pfisterer, J., and Bacon, M., “The Gynecologic Cancer Intergroup (GCIG): history and current status.”, Ann Oncol, vol. 16 Suppl 8, pp. viii39-viii42, 2005.PubMed

S. Camilleri-Broet, Hardy-Bessard, A. C., Le Tourneau, A., Paraiso, D., Levrel, O., Leduc, B., Bain, S., Orfeuvre, H., Audouin, J., Pujade-Lauraine, E., and Group, G. I. N. E. C. O., “HER-2 overexpression is an independent marker of poor prognosis of advanced primary ovarian carcinoma: a multicenter study of the GINECO group”, Ann Oncol, vol. 15, pp. 104-12, 2004.Google Scholar 

S. De Placido, Scambia, G., Di Vagno, G., Naglieri, E., Lombardi, A. V., Biamonte, R., Marinaccio, M., Carteni, G., Manzione, L., Febbraro, A., De Matteis, A., Gasparini, G., Valerio, M. R., Danese, S., Perrone, F., Lauria, R., De Laurentiis, M., Greggi, S., Gallo, C., and Pignata, S., “Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) randomized study”, J Clin Oncol, vol. 22, pp. 2635-42, 2004.Google Scholar 

P. J. Eifel, Winter, K., Morris, M., Levenback, C., Grigsby, P. W., Cooper, J., Rotman, M., Gershenson, D., and Mutch, D. G., “Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01”, J Clin Oncol, vol. 22, pp. 872-80, 2004.Google Scholar 

C. Elie, Geay, J. - F., Morcos, M., Le Tourneau, A., Girre, V., Broet, P., Marmey, B., Chauvenet, L., Audouin, J., Pujade-Lauraine, E., Camilleri-Broet, S., and Group, G. I. N. E. C. O., “Lack of relationship between EGFR-1 immunohistochemical expression and prognosis in a multicentre clinical trial of 93 patients with advanced primary ovarian epithelial cancer (GINECO group)”, Br J Cancer, vol. 91, pp. 470-5, 2004.Google Scholar 

G. F. Fleming, Brunetto, V. L., Cella, D., Look, K. Y., Reid, G. C., Munkarah, A. R., Kline, R., Burger, R. A., Goodman, A., and Burks, R. T., “Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study”, J Clin Oncol, vol. 22, pp. 2159-66, 2004.Google Scholar 

B. Gronlund, Hansen, H. H., Hogdall, C., Hogdall, E. V., and Engelholm, S. A., “Do CA125 response criteria overestimate tumour response in second-line treatment of epithelial ovarian carcinoma?”, Br J Cancer, vol. 90, pp. 377-82, 2004.Google Scholar 

B. Gronlund, Hogdall, C., Hilden, J., Engelholm, S. A., Hogdall, E. V., and Hansen, H. H., “Should CA-125 response criteria be preferred to response evaluation criteria in solid tumors (RECIST) for prognostication during second-line chemotherapy of ovarian carcinoma?”, J Clin Oncol, vol. 22, pp. 4051-8, 2004.Google Scholar 

H. M. Keys, Roberts, J. A., Brunetto, V. L., Zaino, R. J., Spirtos, N. M., Bloss, J. D., Pearlman, A., Maiman, M. A., Bell, J. G., and Group, G. Oncology, “A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study”, Gynecol Oncol, vol. 92, pp. 744-51, 2004.Google Scholar 

D. H. Moore, Blessing, J. A., McQuellon, R. P., Thaler, H. T., Cella, D., Benda, J., Miller, D. S., Olt, G., King, S., Boggess, J. F., and Rocereto, T. F., “Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study”, J Clin Oncol, vol. 22, pp. 3113-9, 2004.Google Scholar 

J. Pfisterer, du Bois, A., Wagner, U., Quaas, J., Blohmer, J. - U., Wallwiener, D., Hilpert, F., and Group, A. Gynakologi, “Docetaxel and carboplatin as first-line chemotherapy in patients with advanced gynecological tumors. A phase I/II trial of the Arbeitsgemeinschaft Gynakologische Onkologie (AGO-OVAR) Ovarian Cancer Study Group”, Gynecol Oncol, vol. 92, pp. 949-56, 2004.Google Scholar 

P. G. Rose, Nerenstone, S., Brady, M. F., Clarke-Pearson, D. L., Olt, G., Rubin, S. C., Moore, D. H., Small, J. M., and Group, G. Oncology, “Secondary surgical cytoreduction for advanced ovarian carcinoma”, N Engl J Med, vol. 351, pp. 2489-97, 2004.Google Scholar 

P. A. Vasey, Jayson, G. C., Gordon, A., Gabra, H., Coleman, R. L., Atkinson, R. J., Parkin, D., Paul, J., Hay, A., Kaye, S. B., and Group, S. Gynaecolog, “Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma”, J Natl Cancer Inst, vol. 96, pp. 1682-91, 2004.Google Scholar 

A. Bezjak, Tu, D., Bacon, M., Osoba, D., Zee, B., Stuart, G. C. E., Roy, J. - A., Piccart, M. J., and Eisenhauer, E., “Quality of life in ovarian cancer patients: comparison of paclitaxel plus cisplatin, with cyclophosphamide plus cisplatin in a randomized study.”, J Clin Oncol, vol. 22, no. 22, pp. 4595-603, 2004.PubMed 

L. Butler, Bacon, M., Carey, M. S., Zee, B., Tu, D., and Bezjak, A., “Determining the relationship between toxicity and quality of life in an ovarian cancer chemotherapy clinical trial.”, J Clin Oncol, vol. 22, no. 12, pp. 2461-8, 2004.PubMed 

S. Pignata and Vermorken, J. B., “Ovarian cancer in the elderly.”, Crit Rev Oncol Hematol, vol. 49, no. 1, pp. 77-86, 2004.PubMed Google Scholar 

G. J. S. Rustin, Quinn, M., Thigpen, T., du Bois, A., Pujade-Lauraine, E., Jakobsen, A., Eisenhauer, E., Sagae, S., Greven, K., Vergote, I. B., Cervantes, A., and Vermorken, J. B., “Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer).”, J Natl Cancer Inst, vol. 96, no. 6, pp. 487-8, 2004.PubMed

M. A. Bookman, Greer, B. E., and Ozols, R. F., “Optimal therapy of advanced ovarian cancer: carboplatin and paclitaxel vs. cisplatin and paclitaxel (GOG 158) and an update on GOG0 182-ICON5”, Int J Gynecol Cancer, vol. 13, pp. 735-40, 2003.Google Scholar 

N. Colombo, Guthrie, D., Chiari, S., Parmar, M. K. B., Qian, W., Swart, A. Marie, Torri, V., Williams, C., Lissoni, A., Bonazzi, C., and Collaborators, I. Collaborat, “International Collaborative Ovarian Neoplasm trial 1: a randomized trial of adjuvant chemotherapy in women with early-stage ovarian cancer”, J Natl Cancer Inst, vol. 95, pp. 125-32, 2003.Google Scholar 

A. du Bois, Luck, H. J., Meier, W., Adams, H. P., Möbus, V., Costa, S., Bauknecht, T., Richter, B., Warm, M., Schröder, W., Olbricht, S., Nitz, U., Jackisch, C., Emons, G., Wagner, U., Kuhn, W., Pfisterer, J., and Group, A. Gynakologi, “A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer”, J Natl Cancer Inst, vol. 95, pp. 1320-9, 2003.Google Scholar 

J. A. Green, “ICON4/AGO-OVAR-2.2: questions about trial design, cost-effectiveness, and clinical benefit”, Lancet, vol. 362, p. 1334; author reply 1334, 2003.Google Scholar 

M. Markman, Liu, P. Y., Wilczynski, S. P., Monk, B. J., Copeland, L., Alvarez, R. D., Jiang, C., Alberts, D. S., Group, S. Oncology, and Group, G. Oncology, “Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial”, J Clin Oncol, vol. 21, pp. 2460-5, 2003.Google Scholar 

G. Newman, “ICON4/AGO-OVAR-2.2: questions about trial design, cost-effectiveness, and clinical benefit”, Lancet, vol. 362, p. 1333; author reply 1334, 2003.Google Scholar 

R. F. Ozols, Bundy, B. N., Greer, B. E., Fowler, J. M., Clarke-Pearson, D. L., Burger, R. A., Mannel, R., DeGeest, K., Hartenbach, E. M., Baergen, R., and Group, G. Oncology, “Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study”, J Clin Oncol, vol. 21, pp. 3194-200, 2003.Google Scholar 

M. K. B. Parmar, Ledermann, J. A., Colombo, N., du Bois, A., Delaloye, J. F., Kristensen, G. B., Wheeler, S., Swart, A. Marie, Qian, W., Torri, V., Floriani, I., Jayson, G. C., Lamont, A., Tropé, C. G., ,, and Collaborators, A. G. O., “Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial”, Lancet, vol. 361, pp. 2099-106, 2003.Google Scholar 

M. J. Piccart, Bertelsen, K., Stuart, G. C. E., Cassidy, J., Mangioni, C., Simonsen, E., James, K., Kaye, S. B., Vergote, I. B., Blom, R., Grimshaw, R., Atkinson, R. J., Swenerton, K. D., Tropé, C. G., Nardi, M., Kaern, J., Tumolo, S., Timmers, P., Roy, J. - A., Lhoas, F., Lidvall, B., Bacon, M., Birt, A., Andersen, J. E., Zee, B., Paul, J., Pecorelli, S., Baron, B., and McGuire, W. P., “Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer”, Int J Gynecol Cancer, vol. 13 Suppl 2, pp. 144-8, 2003.Google Scholar 

M. J. Piccart, Floquet, A., Scarfone, G., Willemse, P. H., Emerich, J., Vergote, I. B., Giurgea, L., Coens, C., Awada, A., and Vermorken, J. B., “Intraperitoneal cisplatin versus no further treatment: 8-year results of EORTC 55875, a randomized phase III study in ovarian cancer patients with a pathologically complete remission after platinum-based intravenous chemotherapy”, Int J Gynecol Cancer, vol. 13 Suppl 2, pp. 196-203, 2003.Google Scholar 

G. J. S. Rustin, “Use of CA-125 to assess response to new agents in ovarian cancer trials”, J Clin Oncol, vol. 21, p. 187s-193s, 2003.Google Scholar 

J. B. Trimbos, Parmar, M. K. B., Vergote, I. B., Guthrie, D., Bolis, G., Colombo, N., Vermorken, J. B., Torri, V., Mangioni, C., Pecorelli, S., Lissoni, A., Swart, A. Marie, Neoplasm, I. Collaborat, Research, E. Organisati, and Neoplasm, Tof Cancer, “International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma”, J Natl Cancer Inst, vol. 95, pp. 105-12, 2003.Google Scholar 

J. B. Trimbos, Vergote, I. B., Bolis, G., Vermorken, J. B., Mangioni, C., Madronal, C., Franchi, M., Tateo, S., Zanetta, G., Scarfone, G., Giurgea, L., Timmers, P., Coens, C., Pecorelli, S., Collaborators, E. O. R. T. C. - A. C. T. I. O. N., Research, E. Organisati, and Neoplasm, Tof Cancer-, “Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial”, J Natl Cancer Inst, vol. 95, pp. 113-25, 2003.Google Scholar 

F. H. van Wijk, Aapro, M. S., Bolis, G., Chevallier, B., van der Burg, M. E. L., Poveda, A. M., de Oliveira, C. F., Tumolo, S., V. di Palumbo, S., Piccart, M. J., Franchi, M., Zanaboni, F., Lacave, A. J., Fontanelli, R., Favalli, G., Zola, P., Guastalla, J. P., Rosso, R., Marth, C., Nooij, M. A., Presti, M., Scarabelli, C., Splinter, T. A., Ploch, E., Beex, L. V., Huinink, W. W. ten Bok, Forni, M., Melpignano, M., Blake, P., Kerbrat, P., Mendiola, C., Cervantes, A., Goupil, A., Harper, P. G., Madronal, C., Namer, M., Scarfone, G., Stoot, J. E., Teodorovic, I., Coens, C., Vergote, I. B., Vermorken, J. B., Research, E. Organisati, and Group, Tof Cancer, “Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group”, Ann Oncol, vol. 14, pp. 441-8, 2003.Google Scholar 

K. Wheatley and Gray, R., “ICON4/AGO-OVAR-2.2: questions about trial design, cost-effectiveness, and clinical benefit”, Lancet, vol. 362, p. 1333; author reply 1334, 2003.Google Scholar 

R. C. Young, Brady, M. F., Nieberg, R. K., Long, H. J., Mayer, A. R., Lentz, S. S., Hurteau, J. A., and Alberts, D. S., “Adjuvant treatment for early ovarian cancer: a randomized phase III trial of intraperitoneal 32P or intravenous cyclophosphamide and cisplatin–a gynecologic oncology group study”, J Clin Oncol, vol. 21, pp. 4350-5, 2003.Google Scholar 

G. B. Kristensen, Vergote, I. B., Stuart, G. C. E., Del Campo, J. M., Kaern, J., Lopez, A. B., Eisenhauer, E., Åvall-Lundqvist, E., Ridderheim, M., Havsteen, H., Mirza, M. R., Scheistroen, M., and Vrdoljak, E., “First-line treatment of ovarian cancer FIGO stages IIb-IV with paclitaxel/epirubicin/carboplatin versus paclitaxel/carboplatin.”, Int J Gynecol Cancer, vol. 13 Suppl 2, pp. 172-7, 2003.PubMed 

M. A. Bookman, Greer, B. E., and Ozols, R. F., “Optimal therapy of advanced ovarian cancer: carboplatin and paclitaxel versus cisplatin and paclitaxel (GOG158) and an update on GOG0182-ICON5.”, Int J Gynecol Cancer, vol. 13 Suppl 2, pp. 149-55, 2003.PubMed 

N. Colombo, Guthrie, D., Chiari, S., Parmar, M. K. B., Qian, W., Swart, A. Marie, Torri, V., Williams, C., Lissoni, A., and Bonazzi, C., “International Collaborative Ovarian Neoplasm trial 1: a randomized trial of adjuvant chemotherapy in women with early-stage ovarian cancer.”, J Natl Cancer Inst, vol. 95, no. 2, pp. 125-32, 2003.PubMed 

J. A. Green, “ICON4/AGO-OVAR-2.2: questions about trial design, cost-effectiveness, and clinical benefit.”, Lancet, vol. 362, no. 9392, p. 1334; author reply 1334, 2003.PubMed 

C. Mangioni, Malmström, H., Reed, N. Simon, Scarfone, G., Poveda, A. M., Tateo, S., Pecorelli, S., Vergote, I. B., Giurgea, L., Coens, C., and Teodorovic, I., “First results of a randomised trial comparing radiotherapy - versus - observation post operatively in patients with uterine sarcomas.”, Int J Gynecol Cancer , vol. 13, no. Suppl 1, 2003.Google Scholar 

M. K. B. Parmar, Ledermann, J. A., Colombo, N., du Bois, A., Delaloye, J. - F., Kristensen, G. B., Wheeler, S., Swart, A. Marie, Qian, W., Torri, V., Floriani, I., Jayson, G. C., Lamont, A., and Tropé, C. G., “Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial.”, Lancet, vol. 361, no. 9375, pp. 2099-106, 2003.PubMed 

M. J. Piccart, Bertelsen, K., Stuart, G. C. E., Cassidy, J., Mangioni, C., Simonsen, E., James, K., Kaye, S. B., Vergote, I. B., Blom, R., Grimshaw, R., Atkinson, R. J., Swenerton, K. D., Tropé, C. G., Nardi, M., Kaern, J., Tumolo, S., Timmers, P., Roy, J. - A., Lhoas, F., Lidvall, B., Bacon, M., Birt, A., Andersen, J. E., Zee, B., Paul, J., Pecorelli, S., Baron, B., and McGuire, W. P., “Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer.”, Int J Gynecol Cancer, vol. 13 Suppl 2, pp. 144-8, 2003.PubMed 

M. L. Rothenberg, Liu, P. Y., Braly, P. S., Wilczynski, S. P., Hannigan, E. V., Wadler, S., Stuart, G. C. E., Jiang, C., Markman, M., and Alberts, D. S., “Combined intraperitoneal and intravenous chemotherapy for women with optimally debulked ovarian cancer: results from an intergroup phase II trial.”, J Clin Oncol, vol. 21, no. 7, pp. 1313-9, 2003.PubMed 

G. J. S. Rustin, “Use of CA-125 to assess response to new agents in ovarian cancer trials.”, J Clin Oncol, vol. 21, no. 10 Suppl, p. 187s-193s, 2003.PubMed 

F. H. van Wijk, Aapro, M. S., Bolis, G., Chevallier, B., van der Burg, M. E. L., Poveda, A. M., de Oliveira, C. F., Tumolo, S., V. di Palumbo, S., Piccart, M. J., Franchi, M., Zanaboni, F., Lacave, A. J., Fontanelli, R., Favalli, G., Zola, P., Guastalla, J. P., Rosso, R., Marth, C., Nooij, M. A., Presti, M., Scarabelli, C., Splinter, T. A. W., Ploch, E., Beex, L. V., Huinink, W. W. ten Bok, Forni, M., Melpignano, M., Blake, P., Kerbrat, P., Mendiola, C., Cervantes, A., Goupil, A., Harper, P. G., Madronal, C., Namer, M., Scarfone, G., Stoot, J. E. G. M., Teodorovic, I., Coens, C., Vergote, I. B., and Vermorken, J. B., “Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group.”, Ann Oncol, vol. 14, no. 3, pp. 441-8, 2003.PubMed Google Scholar

A. du Bois, Meier, W., Luck, H. J., Emon, G., Möbus, V., Schröder, W., Costa, S., Bauknecht, T., Olbricht, S., Jackisch, C., Richter, B., and Wagner, U., “Chemotherapy versus hormonal treatment in platinum- and paclitaxel-refractory ovarian cancer: a randomised trial of the German Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Study Group Ovarian Cancer”, Ann Oncol, vol. 13, pp. 251-7, 2002.Google Scholar 

H. Earl, “ICON3 and chemotherapy for ovarian cancer”, Lancet, vol. 360, p. 2087; author reply 2088, 2002.Google Scholar 

P. M. Flynn, Paul, J., Cruickshank, D. J., and Group, S. Gynaecolog, “Does the interval from primary surgery to chemotherapy influence progression-free survival in ovarian cancer?”, Gynecol Oncol, vol. 86, pp. 354-7, 2002.Google Scholar 

P. Grigsby, Winter, K., Komaki, R., Marcial, V., Eifel, P. J., Doncals, D., Stevens, R., Rotman, M., and Gaffney, D. K., “Long-term follow-up of RTOG 88-05: twice-daily external irradiation with brachytherapy for carcinoma of the cervix”, Int J Radiat Oncol Biol Phys, vol. 54, pp. 51-7, 2002.Google Scholar 

I. Collaborat Group, “Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: The ICON3 randomised trial”, Lancet, vol. 360, pp. 505-15, 2002.Google Scholar 

R. F. Ozols, Markman, M., and Thigpen, J. T., “ICON3 and chemotherapy for ovarian cancer”, Lancet, vol. 360, pp. 2086-7; author reply 2088, 2002.Google Scholar 

S. Pilotti, Oggionni, M., Bohm, S., Pierotti, M. A., and Zunino, F., “ICON3 and chemotherapy for ovarian cancer”, Lancet, vol. 360, pp. 2087-8; author reply 2088, 2002.Google Scholar 

“Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial.”, Lancet, vol. 360, no. 9332, pp. 505-15, 2002.PubMed 

M. E. Gore, Oza, A. M., Rustin, G. J. S., Malfetano, J. H., Calvert, A. H., Clarke-Pearson, D. L., Carmichael, J., Ross, G., Beckman, R. A., and Fields, S. Z., “A randomised trial of oral versus intravenous topotecan in patients with relapsed epithelial ovarian cancer.”, Eur J Cancer, vol. 38, no. 1, pp. 57-63, 2002.PubMed Google Scholar

A. Cull, Howat, S., Greimel, E., Waldenstrom, A. C., Arraras, J., Kudelka, A., Chauvenet, L., Gould, A., Group, E. O. R. T. C. Quality of, and Group, S. Gynaecolog, “Development of a European Organization for Research and Treatment of Cancer questionnaire module to assess the quality of life of ovarian cancer patients in clinical trials: a progress report”, Eur J Cancer, vol. 37, pp. 47-53, 2001.Google Scholar 

S. B. Kaye and Group, S. Gynaecolog, “The integration of docetaxel into first-line chemotherapy for ovarian cancer”, Int J Gynecol Cancer, vol. 11 Suppl 1, pp. 31-3, 2001.Google Scholar 

H. J. Luck, du Bois, A., Weber, B., Pfisterer, J., Goupil, A., Kuhn, W., Barats, J. - C., Blohmer, J. - U., Mousseau, M., Schröder, W., Meier, W., Möbus, V., Richter, B., and Intergroup, A. G. O. - G. I. N. E. C. O., “The integration of anthracyclines in the treatment of advanced ovarian cancer”, Int J Gynecol Cancer, vol. 11 Suppl 1, pp. 34-8, 2001.Google Scholar 

M. Markman, Bundy, B. N., Alberts, D. S., Fowler, J. M., Clarke-Pearson, D. L., Carson, L. F., Wadler, S., and Sickel, J., “Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecol”, J Clin Oncol, vol. 19, pp. 1001-7, 2001.Google Scholar 

J. B. Vermorken, “Intergroup collaboration in ovarian cancer: the Gynecologic Cancer Intergroup (GCIG)”, Int J Gynecol Cancer, vol. 11 Suppl 1, pp. 73-6, 2001.Google Scholar 

H. C. Wagenaar, Pecorelli, S., Vergote, I. B., Curran, D., Wagener, D. J., Kobierska, A., Bolis, G., Bokkel-Huinink, W. T., Lacave, A. J., Madronal, C., Forn, M., de Oliveira, C. F., Mangioni, C., Nooij, M. A., Goupil, A., Kerbrat, P., Marth, C. H., Tumolo, S., Herben, M. G., Zanaboni, F., and Vermorken, J. B., “Phase II study of a combination of cyclophosphamide, adriamycin and cisplatin in advanced fallopian tube carcinoma. An EORTC gynecological cancer group study. European Organization for Research and Treatment of Cancer”, Eur J Gynaecol Oncol, vol. 22, pp. 187-93, 2001.Google Scholar 

J. B. Vermorken, “Intergroup collaboration in ovarian cancer: the Gynecologic Cancer Intergroup (GCIG).”, Int J Gynecol Cancer, vol. 11 Suppl 1, pp. 73-6, 2001.PubMed Google Scholar 

H. C. Wagenaar, Pecorelli, S., Vergote, I. B., Curran, D., Wagener, D. J., Kobierska, A., Bolis, G., Bokkel-Huinink, W. T., Lacave, A. J., Madronal, C., Forn, M., de Oliveira, C. F., Mangioni, C., Nooij, M. A., Goupil, A., Kerbrat, P., Marth, C. H., Tumolo, S., Herben, M. G., Zanaboni, F., and Vermorken, J. B., “Phase II study of a combination of cyclophosphamide, adriamycin and cisplatin in advanced fallopian tube carcinoma. An EORTC gynecological cancer group study. European Organization for Research and Treatment of Cancer.”, Eur J Gynaecol Oncol, vol. 22, no. 3, pp. 187-93, 2001.PubMed Google Scholar

N. Colombo, Parma, G., Bocciolone, L., Franchi, D., Sideri, M., and Maggioni, A., “Medical therapy of advanced malignant epithelial tumours of the ovary”, Forum (Genova), vol. 10, pp. 323-32, 2000.Google Scholar 

M. J. Piccart, Bertelsen, K., James, K., Cassidy, J., Mangioni, C., Simonsen, E., Stuart, G. C. E., Kaye, S. B., Vergote, I. B., Blom, R., Grimshaw, R., Atkinson, R. J., Swenerton, K. D., Tropé, C. G., Nardi, M., Kaern, J., Tumolo, S., Timmers, P., Roy, J. - A., Lhoas, F., Lindvall, B., Bacon, M., Birt, A., Andersen, J. E., Zee, B., Paul, J., Baron, B., and Pecorelli, S., “Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results”, J Natl Cancer Inst, vol. 92, pp. 699-708, 2000.Google Scholar 

I. B. Vergote, “Organization and ethical aspects of randomized trials in gynecologic oncology”, Verh K Acad Geneeskd Belg, vol. 62, pp. 385-95; discussion 395-8, 2000.Google Scholar 

G. H. Windbichler, Hausmaninger, H., Stummvoll, W., Graf, A. H., Kainz, C., Lahodny, J., Denison, U., Muller-Holzner, E., and Marth, C., “Interferon-gamma in the first-line therapy of ovarian cancer: a randomized phase III trial”, Br J Cancer, vol. 82, pp. 1138-44, 2000.Google Scholar 

P. Hoskins, Eisenhauer, E., Vergote, I. B., Dubuc-Lissoir, J., Fisher, B., Grimshaw, R., Oza, A. M., Plante, M., Stuart, G. C. E., and Vermorken, J. B., “Phase II feasibility study of sequential couplets of Cisplatin/Topotecan followed by paclitaxel/cisplatin as primary treatment for advanced epithelial ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group Study.”, J Clin Oncol, vol. 18, no. 24, pp. 4038-44, 2000.PubMed 

J. S. Berek, Bertelsen, K., du Bois, A., Brady, M. F., Carmichael, J., Eisenhauer, E., Gore, M. E., Grenman, S., Hamilton, T. C., Hansen, S. W., Harper, P. G., Horvath, G., Kaye, S. B., Lück, H. J., Lund, B., McGuire, W. P., Neijt, J. P., Ozols, R. F., Parmar, M. K. B., Piccart, M. J., van Rijswijk, R., Rosenberg, P., Rustin, G. J. S., Sessa, C., Thigpen, J. T., Tropé, C. G., Tuxen, M. K., Vergote, I. B., Vermorken, J. B., and Willemse, P. H., “[Epithelial ovarian cancer (advanced stage): consensus conference (1998)].”, Gynecol Obstet Fertil, vol. 28, no. 7-8, pp. 576-83, 2000.PubMed 

M. J. Piccart, Bertelsen, K., James, K., Cassidy, J., Mangioni, C., Simonsen, E., Stuart, G. C. E., Kaye, S. B., Vergote, I. B., Blom, R., Grimshaw, R., Atkinson, R. J., Swenerton, K. D., Tropé, C. G., Nardi, M., Kaern, J., Tumolo, S., Timmers, P., Roy, J. - A., Lhoas, F., Lindvall, B., Bacon, M., Birt, A., Andersen, J. E., Zee, B., Paul, J., Baron, B., and Pecorelli, S., “Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results.”, J Natl Cancer Inst, vol. 92, no. 9, pp. 699-708, 2000.PubMed 

I. B. Vergote, Rustin, G. J. S., Eisenhauer, E., Kristensen, G. B., Pujade-Lauraine, E., Parmar, M. K. B., Friedlander, M. Leonard, Jakobsen, A., and Vermorken, J. B., “Re: new guidelines to evaluate the response to treatment in solid tumors [ovarian cancer]. Gynecologic Cancer Intergroup.”, J Natl Cancer Inst, vol. 92, no. 18, pp. 1534-5, 2000.PubMed Google Scholar 

J. B. Vermorken, “The role of intraperitoneal chemotherapy in epithelial ovarian cancer.”, Int J Gynecol Cancer, vol. 10, no. S1, pp. 26-32, 2000.PubMed Google Scholar 

J. B. Vermorken, “Optimal treatment for ovarian cancer: taxoids and beyond.”, Ann Oncol, vol. 11 Suppl 3, pp. 131-9, 2000.PubMed

M. E. Gore, “ICON2 trial. UK consensus statement on standard practice for chemotherapy in ovarian cancer”, Lancet, vol. 353, pp. 587-8, 1999.Google Scholar 

M. J. Piccart, McGuire, W. P., and Group, G. Oncology, “ICON2 trial. EORTC-GCCG, NOCOVA, NCI-C, Scottish groups, and GOG.”, Lancet, vol. 353, p. 587; author reply 588, 1999.Google Scholar 

C. W. Whitney, Sause, W., Bundy, B. N., Malfetano, J. H., Hannigan, E. V., Fowler, Jr., W. C., Clarke-Pearson, D. L., and Liao, S. Y., “Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study”, J Clin Oncol, vol. 17, pp. 1339-48, 1999.Google Scholar 

J. S. Berek, Bertelsen, K., du Bois, A., Brady, M. F., Carmichael, J., Eisenhauer, E., Gore, M. E., Grenman, S., Hamilton, T. C., Hansen, S. W., Harper, P. G., Horvath, G., Kaye, S. B., Lück, H. J., Lund, B., McGuire, W. P., Neijt, J. P., Ozols, R. F., Parmar, M. K. B., Piccart, M. J., van Rijswijk, R., Rosenberg, P., Rustin, G. J. S., Sessa, C., and Willemse, P. H., “Advanced epithelial ovarian cancer: 1998 consensus statements.”, Ann Oncol, vol. 10 Suppl 1, pp. 87-92, 1999.PubMed 

K. Bertelsen, Grenman, S., and Rustin, G. J. S., “How long should first-line chemotherapy continue?”, Ann Oncol, vol. 10 Suppl 1, pp. 17-20, 1999.PubMed 

M. F. Brady, Thigpen, J. T., Vermorken, J. B., and Parmar, M. K. B., “Randomised trials in ovarian cancer: trial design considerations.”, Ann Oncol, vol. 10 Suppl 1, pp. 75-82, 1999.PubMed 

A. du Bois, Neijt, J. P., and Thigpen, J. T., “First line chemotherapy with carboplatin plus paclitaxel in advanced ovarian cancer--a new standard of care?”, Ann Oncol, vol. 10 Suppl 1, pp. 35-41, 1999.PubMed 

M. J. Piccart, Stuart, G. C. E., Cassidy, J., Bertelsen, K., Parmar, M. K. B., Eisenhauer, E., Kaye, S. B., Tropé, C. G., Swenerton, K. D., Harper, P., and Vermorken, J. B., “Intergroup collaboration in ovarian cancer: a giant step forward.”, Ann Oncol, vol. 10 Suppl 1, pp. 83-6, 1999.PubMed 

G. J. S. Rustin, Nelstrop, A., Bentzen, S. M., Piccart, M. J., and Bertelsen, K., “Use of tumour markers in monitoring the course of ovarian cancer.”, Ann Oncol, vol. 10 Suppl 1, pp. 21-7, 1999.PubMed 

J. B. Vermorken, Harper, P. G., and Buyse, M., “The role of anthracyclines in epithelial ovarian cancer.”, Ann Oncol, vol. 10 Suppl 1, pp. 43-50, 1999.PubMed

I. C. O. N. Collaborators, “ICON2: Randomised trial of single-agent carboplatin against three-drug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) in women with ovarian cancer. International Collaborative Ovarian Neoplasm Study”, Lancet, vol. 352, pp. 1571-6, 1998.Google Scholar

B. K, Kaern, J., Simonsen, E., Piccart, M. J., G, H. Boes, Timmers, P., Roy, J. - A., Pecorelli, S., Stuart, G. C. E., James, K., Cassidy, J., and Kaye, S. B., “Is cisplatin-taxol the standard treatment in advanced ovarian cancer.”, Eur.J.Can. , vol. 33, no. 8, 1997.Google Scholar 

E. Eisenhauer, Vermorken, J. B., and van Glabbeke, M., “Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients [seecomments].”, Ann Oncol, vol. 8, no. 10, pp. 963-8, 1997.PubMed 

E. Eisenhauer, Bacon, M., W, W., C, M. D., R, C., N, O., and Zee, B., “Long term survivors from a European-Canadian Trial of paclitaxel in platinum-pretreated ovarian cancer. ”, Eur J Can , vol. 33, no. 8, 1997.Google Scholar 

P. Harper, “ICON 2 and ICON 3 data in previously untreated ovarian cancer: results to date.”, Semin Oncol, vol. 24, no. 5 Suppl 15, pp. S15-23-S15-25, 1997.PubMed 

R. F. Ozols and Vermorken, J. B., “Chemotherapy of advanced ovarian cancer: current status and future directions.”, Semin Oncol, vol. 24, no. 1 Suppl 2, pp. S2-1-S2-9, 1997.PubMed Google Scholar

S. B. Kaye, Paul, J., Cassidy, J., Lewis, C. R., Duncan, I. D., Gordon, H. K., Kitchener, H. C., Cruickshank, D. J., Atkinson, R. J., Soukop, M., Rankin, E. M., Davis, J. A., Reed, N. Simon, Crawford, S. M., MacLean, A., Parkin, D., Sarkar, T. K., Kennedy, J., Symonds, R. P., and Group, S. Gynaecolog, “Mature results of a randomized trial of two doses of cisplatin for the treatment of ovarian cancer. Scottish Gynecology Cancer Trials Group”, J Clin Oncol, vol. 14, pp. 2113-9, 1996.Google Scholar 

W. P. McGuire, Hoskins, W. J., Brady, M. F., Kucera, P. R., Partridge, E. E., Look, K. Y., Clarke-Pearson, D. L., and Davidson, M., “Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer”, N Engl J Med, vol. 334, pp. 1-6, 1996.Google Scholar 

E. Eisenhauer and Vermorken, J. B., “New drugs in gynecologic oncology.”, Curr Opin Oncol, vol. 8, no. 5, pp. 408-14, 1996.PubMed 

J. B. Vermorken and Pecorelli, S., “Clinical trials in patients with epithelial ovarian cancer: past, present and future.”, Eur J Surg Oncol, vol. 22, no. 5, pp. 455-66, 1996.PubMed

M. Rotman, Pajak, T. F., Choi, K., Clery, M., Marcial, V., Grigsby, P. W., Cooper, J., and John, M., “Prophylactic extended-field irradiation of para-aortic lymph nodes in stages IIB and bulky IB and IIA cervical carcinomas. Ten-year treatment results of RTOG 79-20”, JAMA, vol. 274, pp. 387-93, 1995.Google 

M. E. L. van der Burg, van Lent, M., Buyse, M., Kobierska, A., Colombo, N., Favalli, G., Lacave, A. J., Nardi, M., Renard, J., and Pecorelli, S., “The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer”, N Engl J Med, vol. 332, pp. 629-34, 1995.Google Scholar 

J. B. Vermorken and Hoekman, K., “Chemotherapy for gynecologic malignancies.”, Curr Opin Oncol, vol. 7, no. 5, pp. 457-65, 1995.PubMed

E. Eisenhauer, Huinink, W. W. ten Bok, Swenerton, K. D., Gianni, L., Myles, J., van der Burg, M. E. L., Kerr, I., Vermorken, J. B., Buser, K., and Colombo, N., “European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion”, J Clin Oncol, vol. 12, pp. 2654-66, 1994.Google Scholar 

E. Eisenhauer, Huinink, W. W. ten Bok, Swenerton, K. D., Gianni, L., Myles, J., van der Burg, M. E. L., Kerr, I., Vermorken, J. B., Buser, K., and Colombo, N., “European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion.”, J Clin Oncol, vol. 12, no. 12, pp. 2654-66, 1994.PubMed 

E. Eisenhauer, Bacon, M., Atri, M., M, L., R, N., P, P., E, S., A, F., and N, O., “Radiologic review of response in ovarian cancer: Is it useful? Results from a joint European-Canadian trial. ”, Proc Am Soc Clin Oncol , vol. 13, 1994.Google Scholar

 J. B. Vermorken, “Consolidation therapy in patients with advanced ovarian cancer.”, Eur J Gynaecol Oncol, vol. 15, no. 1, pp. 7-13, 1994.PubMed

D. G. Allen, Baak, J., Belpomme, D., Berek, J. S., Bertelsen, K., Huinink, W. W. ten Bok, van der Burg, M. E. L., Calvert, A. H., Conte, P. F., and Dauplat, J., “Advanced epithelial ovarian cancer: 1993 consensus statements.”, Ann Oncol, vol. 4 Suppl 4, pp. 83-8, 1993.PubMed 

G. J. S. Rustin, van der Burg, M. E. L., and Berek, J. S., “Advanced ovarian cancer. Tumour markers.”, Ann Oncol, vol. 4 Suppl 4, pp. 71-7, 1993.PubMed Google Scholar 

J. T. Thigpen, Bertelsen, K., Eisenhauer, E., Hacker, N. F., Lund, B., and Sessa, C., “Long-term follow-up of patients with advanced ovarian carcinoma treated with chemotherapy.”, Ann Oncol, vol. 4 Suppl 4, pp. 35-40, 1993.PubMed 

M. E. L. van der Burg, Myles, J., Hoskins, P., W, T. Bokkel- Hui, and Eisenhauer, E., “CA-125 is an unreliable marker for monitoring response to taxol therapy in patients with relapsed ovarian cancer. ”, Eur.J.Can. , vol. 29A, no. Suppl.6, 1993.Google Scholar 

J. B. Vermorken, Huinink, W. W. ten Bok, Eisenhauer, E., Favalli, G., Belpomme, D., Conte, P. F., and Kaye, S. B., “Advanced ovarian cancer. Carboplatin versus cisplatin.”, Ann Oncol, vol. 4 Suppl 4, pp. 41-8, 1993.PubMed 

J. B. Vermorken, “The role of chemotherapy in squamous cell carcinoma of the uterine cervix: a review.”, Int J Gynecol Cancer, vol. 3, no. 3, pp. 129-142, 1993.PubMed 

“Advanced ovarian cancer: where do we stand and where do we go? Workshop proceedings. June 15-19, 1993, Elsinore, Denmark.”, Ann Oncol, vol. 4 Suppl 4, pp. 1-88, 1993.PubMed